Abstract:
The invention concerns mixed micelles or micro-aggregates for inducing an immune response containing at least a first lipopeptide comprising a CTL epitope and at least a first lipid motif; and a second lipopeptide comprising at least an auxiliary T epitope and at least a lipid motif, whereof the type can be different from the first lipopeptide motif. Said micelles can be used as medicines and vaccines.

Description:
BACKGROUND OF THE INVENTION 
     The present invention relates to mixed lipopeptide micelles for inducing an immune response. 
     A further object is the use of these micelles for therapeutic purposes. 
     There are two types of effector immune responses: the humoral response due to antibodies, and the cytotoxic response due to CD8 +  T lymphocytes. 
     An effective cytotoxic response requires the presentation of the antigens to the cytotoxic CD8 +  T lymphocytes (CTL), in combination with class I molecules of the Major Histocompatibility Complex (MHC), but also to helper CD4 +  T lymphocytes (HTL) in combination with class II MHC molecules. 
     The use of lipopeptides for inducing a cytotoxic response, in other words the in vivo generation of cytotoxic T lymphocytes, has already been described. In particular, application FR-90 15 870 published under the n° 2 670 787 (Institut Pasteur de Lille, Institut Pasteur, INSERM) discloses lipopeptides composed of a peptide portion comprising 10 to 40 amino acids and a lipid portion which may be derived from fatty acids or steroid groups. 
     These lipopeptides show a good aptitude for inducing a cytotoxic response. However it was advisable to make them able to induce a better quality response by addition of a helper T response whose importance for effective induction and maintenance of the cytotoxic response is known. It was also advisable to make them able to induce a response in as many individuals as possible. 
     BOURGAULT et al. (1994, J. Immunol., 2530-2537) induced a CTL and HTL response from a mixture of lipopeptides, in the form of an emulsion with an oily adjuvant. 
     Nevertheless, it was necessary to add incomplete Freund&#39;s adjuvant (IFA). The immunogenicity of the vaccine preparation used necessarily involved the functional co-presentation of the HTL and CTL units located in one or more lipopeptides in the mixture. However, the effectiveness of the co-presentation of the different units involved depended on the combination with the incomplete Freund&#39;s adjuvant within a very fine emulsion. 
     An article under the name of VITIELLO et al. (1995, J. Clin. Invest., 95, 341-349) raised the possibility of inducing a CTL response in a selected human population (HLA-A2) by using a lipopeptide containing a sequential combination of a CTL HLA-A2 antigenic determinant and a multivalent helper (HTL) antigenic determinant. It should be noted that this study was carried out on a genetically restricted population. 
     This article also reports an experiment during which two types of associations between the HTL antigenic determinant and the CTL antigenic determinant were compared: on the one hand, a covalent sequential combination within the same lipopeptide, and on the other an association by simple mixture of a lipopeptide containing the CTL unit with a peptide containing the HTL unit. The results of this study showed a very clear advantage of the covalent combination compared to the mixture, as performed by the authors, in other words by mixture of solutions containing DMSO and PBS buffer (the peptides or lipopeptides were kept in stock solutions at a concentration of 10-20 mg/ml and diluted with PBS just before use). 
     However, the combination within the same lipopeptide molecule of the cytotoxic and helper antigenic determinants, although able to induce an effective immune response, required the synthesis of long amino acid sequences presenting the multiple antigenic determinants able to combine with several HLA or superfamilies of class I and class II HLA. The covalent combination of all these units within a single molecule presented technical problems not easily overcome, both from the points of view of synthetic methods and analytical characterisation. 
     In any case, this article mentions the combination of a lipopeptide and a peptide, and not of two lipopeptides. For this reason no mixed micelle formation could take place. 
     Another article, published by DON DIAMOND et al. (1997, Blood, 90, n° 5), mentions the immunogenicity of a mixture between a peptide carrying a minimal CTL antigenic determinant (pp 65, sequence 495-503 of the cytomegalovirus matrix protein) and a dipalmitoyl peptide containing an HTL antigenic determinant. The mixture was achieved by mixing solutions in dilute acetic acid or in DMSO, using an ultrasonic treatment for 15 to 30 seconds. 
     This article thus does not describe a mixture of lipopeptides independently containing a CTL antigenic determinant and an HTL antigenic determinant, but the mixture of a lipopeptide containing an HTL antigenic determinant and a nonapeptide corresponding to a minimal CTL antigenic determinant. In addition, there is no mention of the formation of mixed micelles or of micro-aggregates. In this particular case, however, the possibility of direct combination between the nonapeptide and the class I MHC expressed at the surface of the cells could explain the success of the approach followed. The immunogenicity of the preparation indicates that there was effectively co-presentation of the HTL and CTL antigenic determinants by the same antigen-presenting cell; however, the minimal nonapeptide used has the capacity to link directly with the class I MHC at the surface of the antigen-presenting cell, without its presentation by the cell being necessary. 
     The authors conclude by recognising that there are still several obstacles to long-term immunity, which confirms the experimental character of this study. 
     The difficulty of obtaining an immune response depending on a double presentation of the peptides separately presenting the HTL and CTL antigenic determinants is now explained by a publication by STUHLER (1997, Proc. Natl. Acad. Sci. USA, 94, 622-627). To be able to observe the induction of a CTL response, it is absolutely necessary that the HTL and CTL antigenic determinants are present on the surface of the same antigen-presenting cell (APC) to be able to be recognised at the same time by the helper T cells recognising the HTL antigenic determinant and the cytotoxic T cells recognising the CTL antigenic determinant. 
     It follows from the above that compositions containing within the same micelles, or the same micro-aggregates, on the one hand lipopeptides presenting a CTL antigenic determinant and on the other lipopeptides containing an auxiliary T antigenic determinant, i.e. mixed micelles or micro-aggregates, have never, to the knowledge of the applicant, been described. 
     However, as described above, it is absolutely necessary that the two antigenic determinants, cytotoxic and helper T, are present on the surface of the same antigen-presenting cell. 
     In addition to the necessity of a co-presentation of the two antigenic determinants on the surface of the same cell, it is also essential to solubilize the lipopeptides, so as to allow their administration to patients, and their sterilisation by filtration. 
     SUMMARY OF THE INVENTION 
     The applicant has thus endeavoured to find a solution to these different problems. 
     He has shown that, in order to obtain micelles individually formed from all the peptides present in the mixture, whether containing HTL or CTL antigenic determinants, it was necessary to combine the different lipopeptides after having previously dispersed them at the molecular level in a suitable solvent. 
     The object of the present invention is thus micelles or micro-aggregates for inducing an immune response containing at least:
         a first lipopeptide comprising at least one CTL antigenic determinant, or cytotoxic antigenic determinant, and at least one lipid unit, and   a second lipopeptide comprising at least one helper antigenic determinant and at least one lipid unit, which may be of a different type from the first lipopeptide unit.       

    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  represents the chemical structure of the resin of type KNORR-MBHA. 
         FIGS. 2 and 3  show the two-dimensional nuclear magnetic resonance (2DNMR) spectra of a single lipopeptide (lipopeptide ENV) and a mixture of lipopeptides respectively. 
         FIG. 4  shows the helper response of eight macaques immunized with a mixture of lipopeptides. 
         FIGS. 5A to 5F  show the cytotoxic response of macaque n° 109. 
         FIGS. 6A to 6D  show the cytotoxic response of macaque n° 129. 
         FIGS. 7A and 7B  show the cytotoxic response of macaque n° 127. 
         FIGS. 8 ,  9 ,  10  and  11  respectively show the cytotoxic responses of macaques n° 102, 105, 120 and 125. 
         FIGS. 12A ,  12 B and  12 C respectively show the anti-N1, anti-G2 and anti-E cytotoxic activities of PBMC, CD8 +  and CD4 +  cells of the individual V4.1. 
         FIG. 13  shows the cytolytic activity of PBMC of individual V4.5 collected twenty weeks after the beginning of immunization, stimulated in vitro with peptide N2 then tested for their CTL activity against wild vaccine (WT), or this same virus expressing a recombinant NEF protein (NEF, NEF-2, NEF-MN, NEF-A, NEF-ROD). 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     In the scope of the present invention, the expression “immune response” means the whole of the induced immune response, which includes the cytotoxic response and the humoral response. 
     The micelles according to the present invention are not limited to two lipopeptides, but may contain other lipopeptides independently presenting HTL or CTL antigenic determinants. 
     To understand the present invention, helper T antigenic determinant should be understood as meaning an amino acid sequence able to bind with at least one class II HLA receptor, and able to be recognised by helper T lymphocytes. 
     CTL antigenic determinant should be understood as meaning an amino acid sequence able to bind with at least one class I HLA receptor and able to be recognised by cytotoxic T lymphocytes. 
     The helper T antigenic determinants able to bind with several different class II HLA receptors are called multivalent helper antigenic determinants (multivalent HTL). 
     In addition, by micelles or micro-aggregates should be understood aggregates of lipopeptides with a size making them able to be assimilated simultaneously by any antigen-presenting cell (APC) and preferably with a size less than about 1 μm. 
     The mixed micelles according to the invention, in other words comprising lipopeptides containing cytotoxic antigenic determinants and lipopeptides containing helper T antigenic determinants, have the advantage of combining, within the same microvolume which can be assimilated by a single APC, a wide variety of CTL and HTL antigenic determinants, without their covalent combination being necessary, while respecting the required criterion of chemical definition. Micelles which each contain a single type of lipopeptide, containing a CTL antigenic determinant or an HTL antigenic determinant, do not result in an effective co-presentation corresponding to the induction of a strong effector response. 
     In addition, obtaining a CTL response by the use of mixed micro-aggregates or micelles avoids the use of emulsions with oily adjuvants, such as incomplete Freund&#39;s adjuvant, whose use is not approved in human therapeutics. The micelles and micro-aggregates according to the present invention are however compatible with the use of emulsions with clinically acceptable oily vehicles. 
     A further advantage of the mixed micro-aggregates or micelles according to the present invention, each containing at least two types of lipopeptides, is that the solubilization of lipopeptides with a low solubility in water or in clinically acceptable solvents, or insoluble lipopeptides, may be improved by their combination with other lipopeptide(s) with better solubility. 
     The micelles according to the present invention also show the advantage, compared to lipopeptides in which the HTL and CTL units are combined covalently and whose size is limited, such as those described by VITIELLO et al. (1995, cited above), of allowing the combination of a wide variety of units, and thus can be used for the vaccination of human or animal populations not selected on the basis of genetic restriction. 
     The micelles according to the present invention may contain a lipopeptide with at least a CTL antigenic determinant and another lipopeptide containing at least a helper antigenic determinant. However, such micelles may also contain several different lipopeptides containing different cytotoxic antigenic determinants and different lipopeptides with different helper antigenic determinants. 
     The lipid units of the lipopeptides may independently be one or more C 4 -C 18  units, and in particular one or more C 4 -C 18  chains derived from fatty acids, or fatty alcohols, optionally branched and unsaturated or derived from a steroid. 
     They may contain one or two C 4  to C 18  lipid chains linked by a covalent bond to one or two amino acids of the peptide part. They may also be composed of two palmitic acid chains linked to the alpha and epsilon NH 2  groups of a lysine. 
     These lipid units may also be composed of, or contain, a residue of palmitic acid, 2-aminohexadecanoic acid, oleic acid, linoleic acid, linolenic acid, pimelautide, trimexautide, or a derivative of cholesterol, or any other natural lipid component of the cell membranes. 
     The lipopeptides constituting the mixed micelles or micro-aggregates are advantageously water-soluble in a proportion of at least 30% (by weight). These water-soluble lipopeptides have cationic surface-active properties, suitable for providing a solubilizing effect on other lipopeptides in weak acid medium. 
     The non-lipid part contains between 10 and 100, and preferably between 10 and 50 amino acids. The number of amino acids depends on the number of antigenic determinants constituting the non-lipid part of the lipopeptide and on their sizes, on the nature of the lipid part, and the proportions of the lipid and non-lipid parts. 
     The HTL and CTL antigenic determinants used are advantageously antigenic determinants able to bind with several different HLA, otherwise called multivalent or promiscuous antigenic determinants. 
     The HTL antigenic determinant used is preferably composed of the multivalent peptide 830-843 of the tetanus toxin. 
     QYIKANSKFIGITE (SEQ ID NO:1) 
     The glutamine (Q) of this sequence may optionally be acetylated. 
     Other multivalent HTL antigenic determinants may be the multivalent antigenic determinant of hemagglutinin (PREVOST-BLONDEL et al., 1995, J. Virol., vol. 62, n° 12, pages 8046-8055) or the PADRE antigenic determinant (ALEXANDER et al., 1994, Immunity, 1, 751). 
     The CTL antigenic determinant may be any antigenic determinant able to activate cytotoxic CD8 +  T lymphocytes. 
     It is preferably a CTL antigenic determinant of a protein presented by a tumour cell and in particular by a melanoma, a protein from HIV, from hepatitis B virus (HBV) or from papillomavirus, or protein p53. 
     It may in particular be one of the following antigenic determinants:
         antigenic determinants of protein BCR-ABL, resulting from the BCR-Abelson translocation (chronic myeloid leukemia) such as those listed in table 1.   antigenic determinants of protein p53, such as those listed in table 2.       

     The antigenic determinants of protein p53 may in addition be comprised in the sequences 25-35, 63-73, 129-156, 149-156, 187-205, 187-234, 226-264, or 249-264 of this protein.
         antigenic determinants of proteins E 6  or E 7  of human papillomavirus (HPV), such as those listed in table 3.   antigenic determinants of proteins of the HIV-1 virus such as those listed in table 4.   antigenic determinants of melanoma or other tumours, such as those listed in tables 5, 6 and 7 and in particular antigenic determinants of the melan-A/mart-1 antigen of melanoma.       

     Other multivalent CTL antigenic determinants with a capacity to bind to class I HLA ma be those included in the peptide 43-57 of HPV (GQAEPDRAHNIVTF (SEQ ID NO:284)) which contains HLA A2, A24, B7 and B18 antigenic determinants. 
     The CTL antigenic determinants may also be those of parasite antigens, and in particular of  Plasmodium falciparum.    
     The mixed lipopeptide micro-aggregates or micelles according to the present invention may be freeze-dried, then taken up into any clinically acceptable buffer to be administered to the patients to be treated, and in particular to patients to be vaccinated. 
     They may be administered by any administration route used in therapeutics and, as non-limiting examples, by parenteral, percutaneous, oral, or sublingual routes or by intra-pulmonary nebulizer. 
     A further object of the present invention is thus the use of these lipopeptides for the production of a drug or vaccine for inducing a specific immune response, and in particular, for inducing an immune response against cancers such as melanoma, HIV and HBV viruses, papillomavirus, p53 or malaria. 
     Another object of the present invention is a pharmaceutical composition characterized in that it contains a pharmacologically active quantity of one or more of the lipopeptides described above, in addition to pharmaceutically compatible vehicles. 
     The present invention also relates to a method of inducing an immune response against an antigen comprising the administration of micelles or micro-aggregates, such as those described above, to an individual for which such a response is sought. 
     An additional object is a method of immunization against a pathogenic agent comprising the administration of micelles or micro-aggregates such as those described above to an individual for whom such an immunization is sought. Such pathogenic agents, and antigens, may be those listed above. 
     The lipopeptides forming the micelles according to the present invention may be produced by any suitable method known to a person skilled in the art. They may in particular be obtained by the Boc-benzyl or Fmoc-tert-butyl methods, in particular as disclosed in the application FR-90 15 870, which patent application is incorporated herein by reference. 
     The introduction of the lipid chain may be achieved in the solid phase, after selective deprotection of the functional group or groups concerned, as described in the article by DEPREZ et al., (1996, Vaccine, volume 14, n° 5, 375-382). The lipid chain may be introduced onto the ε-NH 2  function of a lysine protected on the α-NH 2  function by an F-moc group. The Fmoc-lys (Palm) obtained may then be used in solid-phase synthesis to produce the lipopeptide. 
     The micelles and micro-aggregates according to the present invention may be obtained by dispersing each lipopeptide in a concentrated acetic acid solution at about 80% concentration, then mixing the solutions thus obtained. 
     The quality of dissolution, i.e. the effective dispersion at the molecular level of each lipopeptide before the preparation of the mixture, is confirmed by the two-dimensional nuclear magnetic resonance method (2DNMR). The resolution of the signal obtained during homonuclear experiments in two dimensions in a 600 MHz field confirms the complete dispersion, at the molecular level, of the lipopeptides in solution. The clarity of the mixture is not a sufficient criterion: in particular, the taking up of the lipopeptides by DMSO or a DMSO/water mixture does not lead, in most cases, to a sufficient dispersion state, which explains the ineffectiveness of the mixture studied by VITIELLO et al. (1995, cited above). Dissolution by acetic acid/water mixtures which are more dilute in acetic acid also does not lead in all cases to the preparation of a mixture of mixed micro-aggregates or micelles containing a statistical proportion of each constituent of the mixture at the microvolume level. In these two cases, even in the presence of an apparently clear mixture, the sterilizing filtration over a 0.22 μm membrane is either impossible, or irregular, with filtration yields which differ according to the constituents, which indicates that at the scale of a particle of this size, the representation of each constituent of the mixture has not been achieved. This micro-heterogeneity compromises the immunogenicity of the mixture, since it comprises the simultaneous capture and presentation of all constituents by a single antigen-presenting cell (APC), in the case of CTL and HTL antigenic determinants present on separate lipopeptides. 
     The present invention is illustrated, without in any way being limited, by the following examples. 
     EXAMPLE 1 
     Preparation of Micelles or Micro-Aggregates According to the Invention 
     1—Description of Lipopeptides Used in the Mixture 
                                                                   Molecular   SEQ ID       Name   Formula   Weight   NO:                                NEF   VGFPVTPQVPLRPMTYKAAVDLSHFLK-   3862.77   2       66   EKGGLK(Pam)-NH 2         NEF   TQGYFPDWQNYTPGPGVRYPLTFGWC-   4017.754   3       117   YKLVPK(Pam)-NH 2         NEF   EWRFDSRLAFHHVARELHPEYFKNK   3451.04   4       182   (Pam)-NH 2         GAG   DLNTMLNTVGGHQAAMQMLKETINEE-   3983.65   5       183   AAEWDRK(Pam)-NH 2         GAG   NPPIPVGEIYKRWIILGLNKIVRMYSPTS-   4063.05   6       253   ILDK(Pam)-NH 2         ENV   TRPNNNTRKSIHIGPGRAFYATGEIIGDI-   4027.69   7           RQAHK(Pam)-NH 2                      
CTL antigenic determinants represented:
 
     
       
         
               
               
               
             
           
               
                   
               
             
             
               
                 RPNNNTRKSI 
                 SEQ ID NO. 8 
                 HLA-B27 
               
               
                 PPIPVGEIY 
                 SEQ ID NO. 9 
                 HLA-B35 
               
               
                 KRWIILGLNK 
                 SEQ ID NO. 10 
                 HLA-B27 
               
               
                 LGLNKIVRMY 
                 SEQ ID NO. 11 
                 HLA-B62 
               
               
                 QVPLRPMTYK 
                 SEQ ID NO. 12, 168, 174, 215 
                 HLA-A-3, A11, 
               
               
                   
                   
                 B27.2 
               
               
                 VPLRPMTY 
                 SEQ ID NO. 13 
                 HLA-B35 
               
               
                 AVDLSHFL 
                 SEQ ID NO. 14 
                 HLA-B62 
               
               
                 AVDLSHFLK 
                 SEQ ID NO. 15, 175 
                 HLA-A11 
               
               
                 TQGYFPDWQNY 
                 SEQ ID NO. 16 
                 HLA-B62 
               
               
                 YFPDWQNYT 
                 SEQ ID NO. 17 
                 HLA-B17, B35 
               
               
                 TPGPGVRYPL 
                 SEQ ID NO. 18, 193 
                 HLA-B7 
               
               
                 RYPLTFGW 
                 SEQ ID NO. 19 
                 HLA-B27.2 
               
               
                 YPLTFGWC 
                 SEQ ID NO. 20 
                 HLA-B18 
               
               
                 AFHHVAREL 
                 SEQ ID NO. 21 
                 HLA-B52 
               
               
                 FLKEKGGL 
                 SEQ ID NO. 22, 200 
                 HLA-B8 
               
               
                   
               
             
          
         
       
     
     This set of antigenic determinants shown above should lead to the induction of CTL responses in a large proportion of the human population, on the condition of being able to benefit from the helper effect of HTL antigenic determinants which, although not defined, are very probably present for simple statistical reasons in any one of the lipopeptides on condition however of bringing together all the antigenic determinants, and thus all the peptide constituents of the mixture, in each micro-unit of volume. 
     2—Synthesis 
     The solid phase approach was selected, using the Fmoc strategy for protecting the α-amine function, and t-Bu for protecting the side chains. The protocol used was a standard protocol based on the synthetic methods described by ATHERTON (Solid-phase synthesis, a practical approach, IRL Press, 1989) and FIELDS and NOBLE (Int. J. Pept. Prot. Res., 1990, 35, 161-214). 
     The Fmoc-Lys(Palm)-OH was coupled to a resin of KNORR-MBHA type ( FIG. 1 ). After deprotection of the alpha-amine function, the first amino acid was coupled (for example Fmoc-Leu-OH in the case of NEF 66). The coupling agent was TBTU (3 eq) in the presence of DIPEA (4.5 eq), with verification of coupling by a calorimetric test. A systematic acetylation was performed after a negative reaction had been obtained with this test, to minimize the risk of obtaining peptides by deletion. This succession of operations was repeated until all the amino acids in the sequence had been added. 
     After the synthesis, and deprotection of the terminal Fmoc group, the peptides were deprotected and cleaved by a TFA/water/DTT mixture (NEF 66, ENV), TFA/water/DTT/Ac-Trp-OH (GAG 183, GAG 253, NEF 117) or TFA/water/EDT/Ac-Trp-OH (NEF 182). 
     The peptides were each purified on a Vydac C18 column which was exclusively used for this purpose, at ambient temperature, with a water-acetonitrile solvent system, in perchlorate or TFA buffer. 
     They were then converted into their acetate form by ion exchange on a Dowex SBR column, then freeze-dried in 40% acetic acid. 
     Each peptide was produced from a single batch of synthesis and purification. No recycling of purification fractions was performed. 
     3—Studies of the Solubility of the Lipopeptides: 
     3-1) Use of Pure Water: 
     The peptides NEF 66, NEF 117, NEF 182 and ENV could be dissolved in pure water, at concentrations of up to 5 mg/ml. Peptide NEF 117 however gave a slightly opalescent solution. Peptides GAG 182 and GAG 253 were not soluble under these conditions. 
     The mixture of lipopeptides was however soluble in pure water, indicating that the hydrophilic lipopeptides were having a solubilizing effect on the less soluble peptides. 
     3-1) Use of DMSO: 
     The dissolution of lipopeptides is often performed using aqueous solutions of DMSO (dimethyl sulfoxide). This very powerful organic solvent is in fact compatible, after dilution, with the majority of biological tests carried out on cells or animals, even humans. The use of DMSO proved effective for good solution of peptides GAG 182 and GAG 253; the solutions obtained could then be diluted with water to reach a final concentration of 1 mg/ml in 20% DMSO/water; in these conditions, most of the peptides gave a clear solution, except GAG 183 for which a suspension was obtained. 
     It is useful to emphasize that even in the case of the clear solutions, and despite the compatibility of DMSO with Durapore filters, the solutions of lipopeptides in DMSO could not be filtered over filters of porosity 0.22 μm, because they exerted a pressure incompatible with the mechanical resistance of the filters. This observation shows the formation of aggregates of size greater than 0.22 μm. In some cases, we found it impossible to filter over filters resistant to solvents, with porosity 1 μm, because of the formation of gels (this size of filter is in fact used to filter concentrated lipopeptide solutions before purification by RP-HPLC). 
     3-3) Use of 25% Concentrated Acetic Acid: 
     The inclusion of the necessary step of sterilizing filtration thus requires the use of an organic solvent more suitable for dissociating the aggregates, compatible after dilution with freeze-drying, and non-toxic at low doses. Acetic acid was tested. 
     A minimum quantity of this solvent was initially used, defined as the quantity giving clear solutions at concentrations of 5 mg/ml: for peptides GAG 183 and GAG 253, 25% acetic acid was used; for the other peptides, dissolution in pure water was performed. 
     The solutions were subjected to nuclear magnetic resonance analysis in a 600 MHz field. It was observed that, despite the apparent clarity of the lipopeptide solutions of this series, even the most hydrophilic lipopeptides formed aggregates of significant size which prevented this type of study, in the absence of resolved signals. 
     Dissolution under these conditions did not lead to statistical dispersion, at the molecular level, of each of the constituents, despite the apparent clarity of the solutions. 
     3-4) Use of 80% Concentrated Acetic Acid: 
     The use of 80% concentrated acetic acid was then tested. The peptides were dissolved at a concentration of 1 mM in 1 ml of 80% acetic acid (corresponding to: NEF 66: 3.86 mg/ml; NEF 117: 4.02 mg/ml; NEF 182: 3.45 mg/ml; GAG 183: 3.98 mg/ml; GAG 253: 4.063 mg/ml; ENV: 4.027 mg/ml). 
     Analysis of the Lipopeptides by Proton NMR at 600 MHz 
     The lipopeptide samples were prepared by dissolving the lipopeptides in a solution of acetic acid (CD3COOD, 99.5% D atoms, EURISO-TOP, France)/H2O; 80:20 (V:V). 4 μl of a 50 mM solution of TMSP [sodium 3-(trimethylsilyl)propanesulfonate] in D2O were added as chemical shift reference. The final concentration of each peptide was 1 mM in at least 2 ml of solvent, which were transferred into 8 mm diameter NMR tubes (WILMAD 513A-7PP, Interchim, France). 
     The proton NMR spectra were performed on a BRUKER DMX600 NMR spectrometer fitted with an 8 mm BBI probe with z gradient, at a sample temperature of 310° K. 
     NOESY (Nuclear-Overhauser effect spectroscopy) experiments in two homonuclear dimensions according to Kumar et al. (1980, Biochem. Biophys. Res. Comm., 95, 1-6) and TOCSY (Total Correlation Spectroscopy) according to Bax and Davis (1985, J. Magn. Reson., 65, 355-360) and Griesinger et al. (1988, J. A. C. S., 110, 7870-7872) were obtained with 2048×512 complex points and processed after multiplication in two dimensions by a sine wave displaced by Π/4 with 2048×1024 points, for a spectral window of 12 ppm. The mixture times were 300 ms for the NOESY and 160 ms for the TOCSY. During the TOCSY mixture time, a MLEV 16 was applied with a B1 field of 7.8 KHz. So as to be under the same temperature conditions, the spin-lock time of the TOCSY was applied without resonance (+ or −1 MHz) in the NOESY. The suppression of water was achieved by using a slight pre-saturation of this signal during the relaxation time and the mixture time of the NOESY. 
     The high-field NMR analysis of the solutions showed perfectly resolved signals, allowing the TOCSY-NOESY experiments, and the complete sequential attribution of each lipopeptide. This result indicates complete dispersion, at the molecular level, of the lipopeptides in 80% acetic acid. 
     The 2D NMR spectrum of peptide ENV is shown on  FIG. 2 . The spectra of all the peptides could be obtained under the same conditions and interpreted. In order to verify if the intermixture of the solutions would change the dispersion of the lipopeptides, a 2D NMR spectrum of a virtual mixture was obtained by superimposing the 6 spectra obtained individually onto a single representation. It was compared with the 2D NMR spectrum actually obtained by mixing the solutions ( FIG. 3 ). The resolution of the signals remained comparable, proving that none of the peptides had altered the solubility of the other constituents of the mixture. The sequence analysis required an accumulation of signals over 120 hours for each lipopeptide, during which period no significant alteration of the peptides was detected, either by NMR or by RP-HPLC. This observation thus allows the use of this solvent for the solubilization of the lipopeptides, their mixture, then filtration, even with a residence time of the order of 1 to 2 hours, conceivably necessary for the handling of relatively large volumes. 
     4—Studies of the Sterilization Filtration Step: 
     4-1 Isolated Lipopeptides: 
     Tests on the sterilizing filtration were performed on 5 mg/ml solutions of each lipopeptide in water for peptides NEF 66, NEF 117, NEF 182 and ENV and in 25% acetic acid for peptides GAG 183 and GAG 253. The filtration yields for 1 ml over Millipore Millex GV SLGV 0130S filters (0.22 μm), followed by freeze-drying, are shown in table 8 (to within the precision of the determination). 
     These results are in agreement with the solution studies performed by NMR, and give information on the size of the aggregates or micelles detected: some peptides form aggregates of size greater than 0.22 μm, and as a result lead to mixtures containing micro-heterogeneities and an improbable simultaneous capture at the scale of the antigen-presenting cell. 
     4-2) Preparation of Different Lipopeptide Mixtures: 
     a) Preparation of Batch CK2. Simple Mixture of Solutions, and Production of a Clear But Micro-Heterogeneous Solution: 
     For the dissolution of the lipopeptides and the preparation of the mixture, solutions of totally clear appearance were intermixed, so as to evaluate the possible contribution of the surface-active character of lipopeptides ENV, NEF 66, NEF 117 and NEF 182. The conditions are summarized in table 9. 
     The solutions obtained were subjected to ultrasonic action to encourage the dispersion of the aggregates, mixed to give a final volume of 5.5 ml, and the mixture was again subjected to ultrasonic action, then diluted with 9.5 ml of water to obtain a final concentration of about 8% in acetic acid (AcOH), compatible with a good quality freeze-drying. This solution, after a final period in the ultrasonic bath, was filtered over Millipore Millex GV SLGV 0130S filters (0.22 μm). The filtration yields for the peptides in the mixture were calculated for each lipopeptide, to give the results shown in the final column of table 9 (to within the precision of the determination). 
     The heterogeneity of the yields depending on the peptide showed the heterogeneity of the solution. Each peptide behaved as if it had been filtered individually: this behaviour was particularly evident for the peptide GAG 253, whose filtration yield from this solution in 8% acetic acid was lower than the yield observed when it was filtered alone from a solution of 25% acetic acid. This result confirms that, despite the apparent clarity of the mixture in dilute acetic solution, the mixture between the lipopeptides had not formed mixed micro-aggregates or micelles which contained in particular the more hydrophobic peptides. The exchanges of the lipopeptides between micelles occurs poorly under these conditions, and the surface-active function of lipopeptides ENV, NEF 66, NEF 117 and NEF 182 could not operate. 
     b) Preparation of Batch CK3: Preparation of Mixed Micelles or Micro-Aggregates not Including Micro-Heterogeneity 
     In order to guarantee complete mixing of the different lipopeptides at the level of each micro-unit of volume, a different strategy was followed:
         each lipopeptide was dissolved in 80% acetic acid so as to exploit the dissociating properties of this solvent.   in order to exploit the cationic surface-active properties expected of the peptides ENV, NEF 66, NEF 117 and NEF 182 in weak acid medium during the dilution step, the lipopeptides were dispersed in 80% acetic acid in the following order: 1: ENV, 2: NEF 66, 3: NEF 117, 4; NEF 182, ending with the dispersion of the two most hydrophobic lipopeptides in a solution now concentrated in dissociating agents: acetic acid and cationic detergents. The fifth lipopeptide introduced was GAG 183 and the sixth GAG 253. An ultrasonic step was used at each stage to ensure effective dispersion of the aggregates.       

     The solutions were mixed, then filtered over Millex GV SLGV 0130S filters (0.22 μm). The filtration required a lower pressure than during the filtration of the 8% solution. The receiver vessels and the filter were then rinsed with water, in sufficient quantity to give a final acetic acid concentration of 8% (final volume 15 ml as before), so as to ensure the quality of the freeze-drying step. The filtration yields of the peptides in the mixture were calculated for each lipopeptide, to give the results listed in the final column of table 10 (to within the precision of the determination). 
     The homogeneity of the yields confirms the homogeneity of the solution resulting from the dispersion at the molecular level at the time of filtration in concentrated acetic acid. The subsequent dilution cannot result in a reorganization of each peptide into monovalent entities, by application of the laws of entropy. This method of preparation of the mixture thus gives mixed micelles which each necessarily contain a statistical representation of each lipopeptide. The surface-active properties of the lipopeptides can operate and guarantee the solubility in water of vaccine doses after freeze-drying as well as the stability of the solutions during the handling time. 
     c) Preparation of Batch CK9 
     The procedure used was the same as for the previous batch, apart from the quantities. The solution of the peptide (20 mg/ml in 80% acetic acid) was filtered in 4 portions, changing the filter before its saturation, using identical membranes (Durapore STERIVEX GV 0.22 μm sterile units (Millipore)), then made up with the water used for rinsing the filters and for dilution. The final volume was 1516 ml (including 154 ml of acetic acid: 10% in final solution). The portion volume was 1.3 ml per dose. The apportioned doses were freeze-dried, and analysed using a validated HPLC determination method. The filtration yield for each lipopeptide is given below in table 11, and takes into account the determination sensitivity of each lipopeptide. 
     During the preparation of this batch, we again observed good homogeneity of the filtration yields, confirming the formation of mixed micelles or micro-aggregates, each micro-unit containing an equivalent proportion of each constituent of the mixture. 
     The mixture after dilution and freeze-drying gave a white powder forming a compact homogeneous cake, which could very easily be taken up into solution in pure water or a solvent able to restore the osmolarity of the solution (5% glucose, 5% mannitol). The solution showed a very slight opalescence. The pH obtained after taking up in a non-buffered solvent was 4.90. Raising the pH by 1 unit caused a slow precipitation: this behaviour contributed to the formation of a deposit during subcutaneous or intramuscular injection. 
     d) Test of Uniformity of Concentration on Batch CK9 
     According to the Pharmacopoeia, powders for parenteral use are subjected to a requirement of uniformity of concentration. The test must be performed on 10 random samples, which are analysed individually for the active ingredient using an appropriate analytical method. The preparation satisfies the test if the concentration of each sample is between 85 and 115% of the average concentration. 
     The test was performed on 15 random samples, taken up in solution and diluted in 80% acetic acid according to a standardized operational procedure, so as always to inject an identical proportion of about 15 μg, defined during preparation of the calibration curve. Each sample was injected three times, the concentration of each active ingredient corresponding to the average of the three values obtained. 
     The values obtained are given in table 12 below. The distribution of the values is clearly statistical. All the values are within a range defined for a two-sided test with P=0.975 (except for three deviant values, all from flask n° 1, which may correspond to a dilution error). The minimum and maximum values defined are within the limits imposed by the Pharmacopoeia (the difference observed was within 4 and 14.95% depending on the peptide, a variation linked to the inherent imprecision of the analysis method). 
     The absence of micro-heterogeneity of the solution was confirmed by the fact that the apportioned vaccine doses satisfied the concentration uniformity test. 
     EXAMPLE 2 
     Preparation of a Mixture of Lipopeptides (SIV-Mortara 1) and Test of Immunogenicity in Macagues 
     1) Preparation of the Batch SIV-MORTARA 1 
     This small batch was prepared in order to perform a pre-clinical test on macaques, to verify the tolerance and immunogenicity. This batch resulted from the mixture of the following lipopeptides: 
     
       
         
               
               
               
             
           
               
                   
               
               
                 Name 
                 Formula 
                 SEQ ID NO: 
               
               
                   
               
             
             
               
                 NEF 101 
                 SVRPKVPLRAMTYKLAIDMSHFIKEKK 
                 23 
               
               
                   
                 (Pam)-NH 2   
               
               
                 NEF 125 
                 EKGGLEGIYYSARRHRILDMYLEK 
                 24 
               
               
                   
                 (Pam)-NH 2   
               
               
                 NEF 155 
                 DWQDYTSGPGIRYPKTFGWLWKLVK 
                 25 
               
               
                   
                 (Pam)-NH 2   
               
               
                 NEF 201 
                 SKWDDPWGEVLKAWKFDPTLAYTYEAK 
                 26 
               
               
                   
                 (Pam)-NH 2   
               
               
                 NEF 221 
                 YTYEAYARYPEELEASQACQRKRLEEGK 
                 27 
               
               
                   
                 (Pam)-NH 2   
               
               
                 GAG 165 
                 KFGAEVVPGFQALSEGCTPYDINQMLNC- 
                 28 
               
               
                   
                 VGDK(Pam)-NH 2   
               
               
                 GAG 246 
                 QIQWMYRQQNPIVGNIYRRWIQLGLQKC- 
                 29 
               
               
                   
                 VRMYNPTNK(Pam)-NH 2   
               
               
                 TT 
                 Ac-QYIKANSKFIGITELKKK(Pam)-NH 2   
                 30 
               
               
                   
               
             
          
         
       
     
     Their mixing was performed from solutions in concentrated acetic acid, as for the preparation of batch CK3. 
     2) Immunogenicity in Macagues. 
     a) Materials and Methods 
     The macaques, respectively numbered 102, 105, 109, 117, 120, 125, 127 and 129 were immunized by subcutaneous injection of the batch prepared above (500 μg), in sterile water, and were reinjected after periods of thirty days and sixty days. 
     These immunizations were performed in accordance with the directives of the European Union. 
     Preparation of CTL Lines 
     Blood cells (PBMC) were isolated by density gradient centrifugation through a lymphocyte separation medium (Pharmacia, Uppsala, Sweden). They were used immediately, or stored at −180° C. in liquid nitrogen. Anti-peptide CTL lines were obtained by cultivating the monkey PBMC (2×10 6  cells/ml) in microtitration plates, in RPMI 1640 supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), L-glutamine (2 mM), non-essential amino acids (1%), sodium pyruvate (1 mM), HEPES buffer (10 mM), 2-mercaptoethanol (2×10 −5  M) and 10% fetal calf serum (FCS) inactivated by heat. 
     The mixture of the seven free peptides, in other words without the lipid unit (5 μM of each), corresponding to the lipopeptide sequences was added to each well. 
     The plates were then incubated for three days at 37° C. and interleukin-2 was added to each plate (10 IU/ml). 
     After seven days and fourteen days, the effector cells were stimulated by addition of new autologous PBMC, which had been in contact with the peptide mixture (5 μM of each) for two hours, then washed and irradiated (4000 rads). 
     Determination of the Proliferation of T Cells 
     PBMC cells (2×10 5  in 200 μl per well) were cultivated in plates containing 1 μg/ml of lipopeptide TT (830-846), and 10 μg/ml of the peptide from tetanus toxin (TT). 
     After five days of culture, 1 μCi of [ 3 H]TdR was added to each well and the incubation was continued for eighteen hours. The cells were then collected using an automatic cell collector then the incorporation of tritiated thymidine was quantified using a scintillation counter. 
     Phenotypic Analysis of CTL Cell Lines 
     The phenotype of the cell lines was determined the day that the chromium release assay was performed, by incubating the cells with anti-CD4 conjugated to FITC (OKT4, Ortho Diagnostic Systems, Raritan, N.J.) and with anti-CD8 conjugated to phycoerythrin (Leu-2a, Becton Dickinson, Mountain View, Calif.) for thirty minutes at 4° C. The cells were washed with PBS buffer, then the percentage of coloured cells was determined using an Epics Elite flow cytometer (Coulter, Margency, France). Antibodies presenting a mixture of isotypes were used as controls. 
     In Vitro Conversion of B (B-LCL) Cell Lines 
     B (B-LCL) cell lines were obtained by incubating series dilutions of PBMC using the supernatant of cell line S 594. This line is infected by baboon herpes virus which immortalizes the cells (herpes virus papio). The B-LCL were then cultivated in the culture medium supplemented with 10% FCS. 
     Chromium Release Assay 
     The target cells were sensitized with the peptides. 10 6  B-LCL cells were incubated either overnight or for 1 hour, respectively, with the long or short peptides (concentration range 10 −5 M-10 −8 M) at 37° C. in a humid atmosphere with 5% CO 2 . In order to obtain the target cells presenting the products of the SIVmac gene, the B-LCL were incubated at a concentration of 10 6  cells/ml with a recombinant vaccine virus (20 PFU/cell) for eighteen hours under the same conditions. The B-LCL were then washed and marked with 100 μCi Na 2   51 CrO 4  (NEN Life Science Products, Courtaboeuf Les Ullis, France) for 1 hour, washed twice and used as target cells. The  51 Cr release was performed in microtitration plates. The cytolytic activity of the anti-SIV cell lines was measured by mixing 5×10 3  target cells marked with chromium with the effector cells, at various ratios of effector cells to target cells, in a final volume of 200 μl/well. The plates were incubated for 4 hours at 37° C., then 100 μl of supernatant was taken from each well and analysed in a gamma radiation counter. 
     The spontaneous release of chromium was determined by incubating the target cells with medium alone. It never exceeded 20% of the total chromium incorporated. 
     The specific release of chromium was measured as follows:
 
100×(experimental  cpm −spontaneous  cpm )/(maximum  cpm −spontaneous  cpm ).
 
     The variation within a sample never exceeded 5%. 
     b) Results 
       FIG. 4  shows the helper T response of the eight macaques. 
       FIGS. 5 to 11  show the cytotoxic response of the macaques. 
     The results of the immunizations with different peptides are summarized in table 13. 
     They show that seven of the eight macaques tested recognized different peptides, with macaques n° 109, 129 and 127 showing a particularly strong response. 
     The effectiveness of the induction of a CTL response confirms that the APC of the animals were able to capture and present one or more CTL antigenic determinants, and simultaneously the strong helper antigenic determinant present in the tetanus anatoxin and recognized by some of the animals. 
     EXAMPLE 3 
     Preparation of a Lipopeptide Mixture (Batch HG 1) for Clinical Tests in Man 
     A mixture of lipopeptides was defined for performing a clinical test (VAC 10), combining within the micelles the same peptide TT with sequences selected on the selection principle developed for VAC 04 (existence of one or more CTL antigenic determinants per sequence).
         the cysteine of peptide NEF 117 was replaced by a leucine: after synthesis and tests on cellular tests of several analogs of the CTL antigenic determinant nonapeptide containing this amino acid, it was observed that this replacement was possible; this modification avoided the stability problems due to the formation of a disulfide bridge.   the peptide GAG 17 was selected from among other candidates for its strong cationic surface-active character, able to help to keep the other peptides in solution, and in particular GAG 253, which was retained in the mixture because of its immunogenicity in man.       

     The composition of this mixture, in which Pam represents a unit derived from palmitic acid and Ac the acetyl group, was the following: 
     
       
         
               
               
               
             
               
               
               
             
           
               
                   
               
               
                 Name 
                 Formula 
                 SEQ ID NO: 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 GAG 17 
                 EKIRLRPGGKKKYKLKHIVK(Pam)-NH 2   
                 31 
               
               
                 GAG 253 
                 NPPIPVGEIYKRWIILGLNKIVRMYSPTSIL- 
                 6 
               
               
                   
                 DK(Pam)-NH 2   
               
               
                 POL 325 
                 AIFQSSMTKILEPFRKQNPDIVIYQYMDDL- 
                 32 
               
               
                   
                 YK(Pam)-NH 2   
               
               
                 NEF 66 
                 VGFPVTPQVPLRPMTYKAAVDLSHFLKE- 
                 2 
               
               
                   
                 KGGLK(Pam)-NH 2   
               
               
                 NEF 116 
                 HTQGYFPDWQNYTPGPGVRYPLTFGWL- 
                 33 
               
               
                   
                 YKLK(Pam)-NH 2   
               
               
                 TT 
                 Ac-QYIKANSKFIGITELKKK(Pam)-NH 2   
                 30 
               
               
                   
               
             
          
         
       
     
     This set of peptides was synthesized as described in the previous examples. The mixture of solutions was performed on a sample of 5 mg of each peptide, dissolved at a concentration of 20 mg/ml in 80% acetic acid then mixed in the following order: 1: GAG 17; 2: NEF 66; 3: NEF 116; 4: TT; 5: GAG 253; 6: POL 325. 
     The yields from the operation of filtering the concentrated acetic acid solutions, followed by a dilution with water, proved comparable to the yields observed for the same operations with the mixture CK3 (to within the precision of the determination). The homogeneity of the solubilities and the behaviour during the sterilizing filtration despite the heterogeneities of their individual chemical behaviour indicated the formation of mixed micelles. 
     EXAMPLE 4 
     Preparation of a Mixture of Lipopeptides Derived from Antigen LSA3 for Pre-Clinical Vaccination Tests Against the Intrahepatic Stage of  Plasmodium falciparum , Performed in Mice and Chimpanzees, then a Clinical Test in Man 
     
       
         
               
               
               
             
           
               
                   
               
               
                 Name 
                 Formula 
                 SEQ ID NO: 
               
               
                   
               
             
             
               
                 LSA3 CT1 
                 LLSNIEEPKENIIDNLLNNIK(Pam)-NH 2   
                 34 
               
               
                 LSA3 NR1 
                 Ac-DELFNELLNSVDVNGEVKENILEES- 
                 35 
               
               
                   
                 QK(Pam)-NH 2   
               
               
                 LSA3 NRII 
                 Ac-LEESQVNDDIFNSLVKSVQQEQQHN- 
                 36 
               
               
                   
                 VK(Pam)-NH 2   
               
               
                 LSA3 RE 
                 K(Pam)VESVAPSVEESVAPSVEESVAEN- 
                 37 
               
               
                   
                 VEESVAENV-NH 2   
               
               
                   
               
             
          
         
       
     
     This set of peptides was synthesized as described in example 1. The mixture of solutions was performed on a sample of 5 mg of each peptide previously dissolved at a concentration of 20 mg/ml in 80% acetic acid then mixed in the following order: 1: LSA3 NRI; 2: LSA3 NRII; 3: LSA3 CT1; 4 LSA3 RE. The yields from the operation of filtering the concentrated acetic acid solutions, followed by a dilution with water, proved comparable for all the lipopeptides. 
     EXAMPLE 5 
     Study of the Immune Response in Man after Injection of Micelles from Batch CK9 
     1. Materials and Methods 
     Micelles Used: 
     The micelles which were injected were obtained as described in example 1 for batch CK9. 
     Long and Short Peptides. 
     The following long peptides corresponding to the immunogenic lipopeptides were synthesized (the positions of the amino acids on proteins NEF, GAG and ENV are given in parentheses): N1 (NEF 66 to 97), N2 (NEF 117 to 147), N3 (NEF 182 to 205), G1 (GAG 183 to 214), G2 (GAG 253 to 284) and E (ENV 303 to 335). 
     The following short peptides, including the lipopeptide sequences already known to be the minimal CTL antigenic determinants, were synthesized by Neosystem (Strasbourg, France): 
     NEF 121-128, NEF 137-145, NEF 184-191 and NEF 195-202 restricted to HLA-A1. 
     NEF 136-145, NEF 190-198 and GAG 183-191 restricted to HLA-A2. 
     NEF 73-82, NEF 84-92 and EBNA 4 (SEQ ID NO:225) 416-424HLA restricted to HLA-A11. 
     NEF 90-97 and NEF 182-189 restricted to HLA-B8. 
     NEF 134-141 and GAG 263-272 (SEQ ID NO:10) restricted to HLA-B27. 
     NEF 135-143 restricted to HLA-B18. 
     Immunization Protocol: 
     Volunteers were immunized by subcutaneous injection of the micelles, or the six corresponding lipopeptides, in the presence of QS21 adjuvant. The lipopeptides or micelles were injected in different ways depending on the individual. 
     Volunteers V4.6, V4.15, V4.16, V4.17, V4.18, and V4.28 were immunized with the six lipopeptides in the form of micelles. 
     Volunteer V4.6 received 250 μg of each of the lipopeptides. 
     Volunteers V4.15, 4.16, V4.17, V4.18, and V4.28 were immunized with 500 μg of each of the six lipopeptides. 
     Volunteers V4.5, V4.1, V4.19, V4.21, V4.32 and V4.34 were immunized with the six lipopeptides in the presence of QS21 adjuvant. 
     Volunteer V4.5 received 100 μg of the 6 lipopeptides, while volunteers V4.1, V4.19, V4.21, V4.32 and V4.34 each received 500 μg of the six lipopeptides. 
     All the volunteers were immunized three times with the mixture of the six lipopeptides, the two later injections being performed 4 weeks and 16 weeks respectively after the first injection. 
     Blood samples were taken after the first injection (hereafter referred to as week 0) and 20 weeks after the first injection (week 20). 
     Peripheral blood mononuclear cells (PBMC) and serum were isolated by conventional methods, and frozen. 
     ELISA Detection of HIV Anti-Peptide Antibodies of Immunoglobulin G (IgG) Type. 
     Wells of polystyrene plates were covered with 5 μg/ml of the peptides (N1, N2, N3, G1, G2 or E) overnight at 4° C. Saturation was performed using a PBS solution containing 0.1% Tween 20 and 3% bovine serum albumin (BSA). Diluted serums ( 1/100) were incubated in the covered wells overnight at 4° C. and the bound antibodies were detected using goat anti-human IgG conjugated with alkaline phosphatase ( 1/5000, Sigma). The phosphatase activity was measured using 4-methyl umbelliferyl phosphate as substrate (Sigma), and the fluorescence measurement was performed at 360/460 nm in a Cytofluor 230.0 (Millipore). 
     Measurement of the T Cell Responses Directed Against HIV Peptides. 
     PBMC (10 5  per well) were cultivated in complete medium with 1 μg/ml or 0.2 μg/ml of the soluble peptides (N1, N2, N3, G1, G2 or E). The proliferation was determined after 5 days culture by added 1 μCi/well of tritiated thymidine (NEN, Paris) 12 hours before their collection. 
     The capacity of the PBMC to proliferate in vitro was verified using independent cultures performed over 5 days with phytohemagglutinin A (PHA) of PPD (Tuberculin purified derivative Reference Statens Serumins Institute n° 2390), tetanus toxin (TT) and SEB (enterotoxin B of  Staphylococcus  golden, Reference Sigma S4881), at 1 μg/ml and 10 μg/ml respectively. 
     Removal of the CD4 +  and CD8 +  T cells of the PBMC was performed with anti-mouse immunoglobulins and by complement activation. To summarize, 10 7  PBMC were incubated in 1 ml of medium lacking bovine serum albumin for 30 minutes at 4° C. with 2 μg of monoclonal antibody OKT4 or OKT8 (Ortho Diagnostic Systems). 
     1 ml of diluted rabbit serum complement (Hoechst Behring, Reuil, France) was added over 45 minutes at 37° C. The cell suspension was washed twice so as to remove the unbound complement. The resuspended cells were analysed using flow cytometry. Analysis of the phenotypes using anti-CD4 +  and anti-CD8 +  antibodies was performed to verify the enrichment. Finally, the cells resulting from the removal of the CD4 +  and CD8 +  cells were tested in a proliferation test. 
     Preparation of CTL Cell Lines 
     In vitro stimulation of the PBMC was performed by mixing 106 PBMC (responsive cells) with 106 irradiated stimulant cells (autologous PBMC incubated for 2 hours with different peptides) in complete RPMI culture medium (RPMI 1640 supplemented with 100 U/ml of penicillin, 100 μg/ml of streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM Hepes, nonessential amino acids and 10% heat-inactivated bovine serum albumin). 
     10 U/ml of interleukin-2 were added after 3 days. The responsive cells were restimulated each week for 3 or 4 weeks using peptides incubated with autologous PBMC (prepared in the same way as on day 0), in a medium supplemented with 10 U/ml of interleukin-2. After 3 or 4 stimulations, the CTL cells were tested using the EBV autologous cell line as target overnight with 10 μg of the different peptides (N1, N2, N3, G1, G2 or E) for 10 6  cells. 
     In order to obtain the target cells presenting the products of the HIV gene, EBV target cells were infected, at a rate of 10 6  cells/ml, with a wild type (WT) vaccine virus or with HIV-1/LAI, HIV-1/MN, HIV/A or HIV/ROD NEF recombinant vaccine viruses overnight (20 PFU/cell). 
     The different target cells were then washed and marked with 100 μCi of Na 2   51 CrO 4  (NEN Life Science Products, Les Ullis, France). 
     The cytolytic activity was measured in a  51 Cr release test, over 4 hours. The average spontaneous release did not exceed 20% of the total  51 Cr incorporation. 
     The results are expressed as follows:
 
specific release of chromium=100×(measured  cpm /spontaneous  cpm )/(maximum  cpm −spontaneous  cpm ).
 
     The removal of the CD4 +  and CD8 +  cells from the PBMC was performed as described above. 
     ELISPOT γ-Interferon Test 
     96-Well microcells plates (MultiScreen-HA, Millipore S.A., Molsheim, France) were covered with 5 μg/ml of mouse anti-human-γ-interferon antibody, as capture antibody (Genzyme Corporation, Cambridge, Mass., USA) overnight at 4° C. 
     After washing, the wells were saturated with complete RMPI medium and PBMC which had been freshly isolated, or kept cold, were added (2×10 5  cells per well) with different peptides corresponding to the minimal CD8 +  antigenic determinants (10 μg/ml). 
     After 24 hours incubation at 37° C. in an incubator (5% CO 2 ), the plates were washed and incubated for 2 hours with 100 μl rabbit anti-human-γ-interferon polyclonal antibody ( 1/250, Genzyme). After washing, a rabbit anti-IgG-biotin conjugate ( 1/500, Boehringer Mannheim France S.A., Meylan, France) was incubated for 1 hour. Finally, extravidine marked with alkaline phosphatase (Sigma-Aldrich Chimie S.A.R.L., St Quentin Fallavier, France) was added over 1 hour. 
     100 μl of alkaline phosphatase chromogenic substrate (Bio Rad Laboratories, Hercules, Calif., USA) were added to develop the spots. The blue spots were then counted using a microscope. 
     The negative control consisted of PBMC incubated alone in the medium, or incubated with a peptide corresponding to a CD8 +  antigenic determinant derived from the HIV virus presented by adapted HLA. 
     The positive control consisted of activating the PBMC with 50 mg/ml of PMA (Phorbol myristate acetate, reference Sigma P 8139) and 500 ng/ml of ionomycin (100 to 300 PBMC per well were added). 
     This strong mitogen stimulation allowed measurement of the viability of the T lymphocytes, and verification of the quality of the storage in the cold. 
     2. Results 
     Tolerance of the Treatment. 
     The secondary effects from the injection of the lipopeptides were not serious. An epidermal reaction was observed at the injection site. Local reactions consisted of small erythemas lasting only 24 to 48 hours. These effects were in no case associated with systemic symptoms. These observations show that the lipopeptides are well tolerated in normal individuals. 
     Specific Induction of a Humoral Response Against HIV-1 Peptides 
     Serum samples were collected before the start of the vaccinations (week 0) and at the twentieth week, after the third injection. 
     The serums from the immunized volunteers were tested by ELISA for the presence of IgG antibody directed against the NEF (N1, N2, N3), GAG (G1, G2), and ENV (E) peptides 
     No IgG specific for the HIV peptides was detected before the injection in the twelve subjects listed in table 14. 
     At the twentieth week, anti-N1 IgG antibodies were detected in five of the vaccinated subjects (V4.6, V4.28, V4.1 (SQ21), V4.32 (QS21), and V4.34 (QS21)), and anti-N2 IgG antibodies were detected in the serums of ten of the subjects, among the twelve vaccinated. No antibody of type anti-N3 IgG was detected. The titration in anti-N2 antibody was negative in the serums of individuals V4.17 and V4.18. The antibody titration was three to five times 1 greater than that of the negative control in the serums of V4.15, V4.16, V4.1 (QS21), V4.5 (QS21) and V4.21 (QS21). The antibody titration was five to ten times greater than that of the negative control in the serums of V4.6, V4.19 (QS21), and V4.28. Finally, the serums of patients V4.32 (QS21) and V4.34 (QS21) showed antibody titration at least 10 times greater than that of the negative control. 
     After 3 injections, no anti-G1 IgG antibody was detected, but anti-G2 IgG antibodies were detected in the serums of the 12 individuals vaccinated. The anti-G2 antibody titration was 2 to 3 times greater than that of the negative control for patient V4.18 (QS21), the antibody titration was 5 to 10 times greater than that of the negative control for individuals V4.16, V4.17, V4.5 (QS21), V4.19 (QS21) and V4.21 (QS21). The serums of patients V4.6, V4.15, V4.28, V4.1 (QS21), V4.32 (QS21) and V4.34 (QS21) had an antibody titration more than ten times greater than that of the negative control. The serums of 6 of the 12 individuals tested, V4.28, V4.1 (QS21), V4.5 (QS21), V4.19 (QS21), V4.32 (QS21) and V4.34 (QS21) contained specific anti-E antibodies. 
     Specific Helper T Cell Response of the HIV-1 Virus Peptides. 
     The proliferative responses with respect to the soluble peptides obtained with the PBMC cells of the different individuals vaccinated are shown in table 15. 
     The NEF, GAG and ENV peptides caused proliferation of the donor PBMC only, after the vaccination. The PBMC of the individuals immunized with the lipopeptides (with or without QS21 adjuvant) proliferated against at least one peptide after 20 weeks (4 weeks after the third injection, for 8 subjects out of 10 given in table 15). 
     No proliferation was observed for the PBMC of individuals V4.15 and V4.17. 
     The PBMC of individual V4.6 proliferated in response to peptides N3, G1 and G2 with a proliferation index of between 4 and 10. An induction of the proliferation in response to G1, G2 and E was observed with the PBMC of individual V4.16. The PBMC of individual V4.28 were able to proliferate in response to peptides N1, N3, G2 and E. A proliferative response against peptides N1, G2 and E was observed for the PBMC of vaccinated individual V4.5. 
     A strong proliferation was observed in response to peptides N1, G2 and E with the PBMC of individual V4.19 (QS21), which in addition were able to proliferate in the presence of N2 and N3. 
     The PBMC of individual V4.21 proliferated in the presence of N1 and G2, while those of individuals V4.32 proliferated only in the presence of G2. 
     A proliferative response was observed in the presence of N1, N3, G2 and E with the PBMC of individual V4.34 (QS21). 
     Overall the third immunization with the lipopeptides induced a proliferative response against peptide N1 for five of the ten subjects treated, against N2 for one of the ten subjects treated, N3 for four of the ten subjects treated, G1 for two of the ten subjects treated, G2 for eight of the ten subjects treated, and finally E for five of the ten subjects treated. 
     The removal experiments performed with the PBMC from the different individuals vaccinated showed that the proliferation of the PBMC recovered after twenty weeks occurred preferentially via the helper CD4 +  T cells. 
     Induction of CTL Activity Specific to HIV 
     The PBMC obtained before and after the immunizations were stimulated in vitro and tested for their CTL activity specific to HIV. 
     The results of representative experiments are given in table 16. 
     The specific CTL activity was tested against the EBV autologous cell line, incubated with or without the NEF, GAG and ENV peptides. No anti-HIV response was detected with the PBMC recovered before the immunization. A specific CTL activity was detected in the PBMC collected three weeks after the immunization for nine of the twelve individuals. 
     Table 16 summarizes the cytotoxic activity of eight of the vaccinated individuals, the activity of one other individual being shown in  FIG. 12 . 
     At least one peptide contained in the lipopeptide vaccine induced specific CTL effector cells recognizing the HIV peptides. 
     For example, the PBMC of individual V4.6 recognized in a cytotoxic test the EBV autologous cells stimulated with peptides G2 and E. The PBMC of individual V4.16 recognized peptide N3 and E. The percentage of lysis was variable, weak for individual V4.16 recognizing peptide N3, intermediate for individual V4.18 with peptide N1 and strong for individual V4.5 (QS21) with peptides N2 and G2. 
     A specific CTL activity was also generated against peptides containing a minimal CD8 +  HIV antigenic determinant (individuals V4.16 and V4.28). 
     In order to evaluate whether the effector cells are CD8 +  T cells, as might be expected for the CTL specific for class-I restricted antigens, the CD8 +  or CD4 +  T lymphocytes were removed from the PBC and a cytotoxicity test was performed. 
     In representative experiments performed with the PBMC of individual V4.1 ( FIG. 12 ), an effective lysis was observed of the autologous EBV cells incubated with the HIV peptides, for the PBMC and the CD8 +  cells. Enrichment in CD8 +  cells increased the percentage of specific lysis. These results confirm that the anti-HIV cytotoxic activity operates via CD8 +  T cells. 
     It was also important to determine whether the cytotoxic T cells (CTL) recognized and lysed cells infected with the virus. 
     PBMC from individual V4.5, collected 20 weeks after immunization, and stimulated in vitro with peptide N2, were thus tested for their CTL activity against autologous targets infected with different viruses expressing the recombinant NEF protein. The results of representative experiments are given in  FIG. 13 . Anti-peptide N2 CTL obtained from individual V4.5 (QS21) recognized an antigen naturally modified by autologous EBV-LCL infected with recombinant viruses of the vaccine coding for the HIV-NEF genes obtained from different strains of HIV. 
     For the same effector/target ratio, CTL specific to the HIV virus recognized NEF-LAI and NEF-MN with the same effectiveness. A lower percentage of specific lysis was obtained for the NEF-A protein or the NEF-ROD protein. 
     These results show that the CTL obtained after vaccination with the lipopeptides are able to recognize different strains of the HIV virus. 
     CD8 +  T Cells Secreting γ-Interferon Ex-Vivo, Specific to the HIV Virus 
     Effector CD8 +  T cells may exercise a lytic activity and/or produce lymphokines. The quantity of CD8 +  T cells secreting γ-interferon was thus evaluated by a specific ELISPOT test. 
     A recent study has shown that the intracellular inactivation of the hepatitis B virus occurs via CD8 +  T cells secreting specific and cytotoxic γ-interferon, which induced a protective immunity. This approach was used to identify the minimal antigenic determinants of CD8 +  T cells by sensitization of PBMC with the short peptides. All the short peptides used have already been described as being CTL antigenic determinants (see above). 
     An ELISPOT has also been used to quantify ex vivo the number of CD8 +  T cells secreting γ-interferon specific to HIV peptides in the PBMC of the vaccinated subjects (table 17). 
     CONCLUSION 
     This study has shown that a lipopeptide vaccine in the form of micelles, and without adjuvant, containing different HIV antigenic determinants contained in the viral proteins NEF, GAG and ENV of the HIV virus, is able to induce a strong and persistent multi-antigenic determinant B and T response in man. 
     
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 1 
               
             
             
               
                   
               
               
                 Antigenic determinants of BCR-ABL 
               
             
          
           
               
                   
                   
                   
                   
                 Seq. 
                 Fixation 
               
               
                   
                 Peptide 
                   
                 Sequence 
                 I.D. No. 
                 to HLA 
               
               
                   
                   
               
               
                   
                  247-255 
                   
                 EDAELNPRF 
                 38 
                 B44 
               
               
                   
                  488-496 
                   
                 SELDLEKGL 
                 39 
                 B44 
               
               
                   
                  768-776 
                   
                 DELEAVPNI 
                 40 
                 B44 
               
               
                   
                  901-934 
                 b2a2 
                 KEDALQRPV 
                 41 
                 B44 
               
               
                   
                  902-935 
                 b2a2 
                 EDALQRPVA 
                 42 
                 B44 
               
               
                   
                  986-994 
                   
                 GEKLRVLGY 
                 43 
                 B44 
               
               
                   
                 1176-1184 
                   
                 EDTMEVEEF 
                 44 
                 B44 
               
               
                   
                 1252-1260 
                   
                 MEYLEKKNF 
                 45 
                 B44 
               
               
                   
                 1691-1699 
                   
                 NEEAADEVF 
                 46 
                 B44 
               
               
                   
                  49-57 
                   
                 VNQERFRMI 
                 47 
                 B8 
               
               
                   
                  580-588 
                   
                 LFQKLASQL 
                 48 
                 B8 
               
               
                   
                  722-730 
                   
                 ARKLRHVFL 
                 49 
                 B8 
               
               
                   
                  786-794 
                   
                 ALKIKISQI 
                 50 
                 B8 
               
               
                   
                  886-893 
                   
                 CVKLQTVH 
                 51 
                 B8 
               
               
                   
                  928-936 
                 b3a2 
                 KALQRPVAS 
                 52 
                 B8 
               
               
                   
                 1830-1838 
                   
                 GAKTKATSL 
                 53 
                 B8 
               
               
                   
                 1975-1983 
                   
                 IQQMRNKFA 
                 54 
                 B8 
               
               
                   
                 1977-1984 
                   
                 QMRNKFAF 
                 55 
                 B8 
               
               
                   
                  252-260 
                   
                 NPRFLKDNL 
                 56 
                 B7 
               
               
                   
                  329-338 
                   
                 TPDCSSNENL 
                 57 
                 B7 
               
               
                   
                  693-701 
                   
                 TPRRQSMTV 
                 58 
                 B7 
               
               
                   
                 1058-1066 
                   
                 SPGQRSISL 
                 59 
                 B7 
               
               
                   
                 1196-1205 
                   
                 HPNLVQLLGV 
                 60 
                 B7 
               
               
                   
                 1560-1569 
                   
                 SPKPSNGAGV 
                 61 
                 B7 
               
               
                   
                 1717-1725 
                   
                 KPLRRQVTV 
                 62 
                 B7 
               
               
                   
                 1878-1884 
                   
                 SPAPVPSTL 
                 63 
                 B7 
               
               
                   
                  36-44 
                   
                 ERCKASIRR 
                 64 
                 B27 
               
               
                   
                  71-79 
                   
                 DRQRWGFFRR 
                 65 
                 B27 
               
               
                   
                  575-583 
                   
                 QRVGDLFQK 
                 66 
                 B27 
               
               
                   
                  834-842 
                   
                 FRVHSRNGK 
                 67 
                 B27 
               
               
                   
                  642-650 
                   
                 LLYKPVDRV 
                 68 
                 A2 
               
               
                   
                  684-692 
                   
                 FLSSINEEI 
                 69 
                 A2 
               
               
                   
                  708-716 
                   
                 QLLKDSFMV 
                 70 
                 A2 
               
               
                   
                  714-722 
                   
                 FMVELVEGA 
                 71 
                 A2 
               
               
                   
                  817-825 
                   
                 KLSEQESLL 
                 72 
                 A2 
               
               
                   
                  881-889 
                   
                 MLTNSCVKL 
                 73 
                 A2 
               
               
                   
                  908-917 
                   
                 GLYGFLNVIV 
                 74 
                 A2 
               
               
                   
                  912-920 
                   
                 FLNVTVHSA 
                 75 
                 A2 
               
               
                   
                 1240-1248 
                   
                 VLLYMATQI 
                 76 
                 A2 
               
               
                   
                 1903-1911 
                   
                 FIPLISTRV 
                 77 
                 A2 
               
               
                   
                 1932-1940 
                   
                 VVLDSTEAL 
                 78 
                 A2 
               
               
                   
                  50-58 
                   
                 NQERFRMIY 
                 79 
                 Al 
               
               
                   
                  223-231 
                   
                 VGDASRPPY 
                 80 
                 Al 
               
               
                   
                  549-558 
                   
                 KVPELYEIHK 
                 81 
                 A3/A11 
               
               
                   
                  583-591 
                   
                 KLASQLGVY 
                 82 
                 A3/A11 
               
               
                   
                  715-724 
                   
                 MVELVEGARK 
                 83 
                 A3/A11 
               
               
                   
                  916-923 
                   
                 IVHSATGFK 
                 84 
                 A3/A11 
               
               
                   
                  920-928 
                 b3a2 
                 ATGFKQSSK 
                 85 
                 A3/A11 
               
               
                   
                  924-932 
                 b3a2 
                 KQSSKALQR 
                 86 
                 A3/A11 
               
               
                   
                 1156-1165 
                   
                 EVYEGVWKKY 
                 87 
                 A3/A11 
               
               
                   
                 1311-1320 
                   
                 SLAYNKFSIK 
                 88 
                 A3/A11 
               
               
                   
                 1499-1509 
                   
                 NLFSALIKK 
                 89 
                 A3/A11 
               
               
                   
                 1724-1734 
                   
                 TVAPASGLPHK 
                 90 
                 A3/A11 
               
               
                   
                 1905-1914 
                   
                 LISTRVSLRK 
                 91 
                 A3/A11 
               
               
                   
                 1922-1930 
                   
                 RIASGAITK 
                 92 
                 A3/A11 
               
               
                   
                  924-936 
                 b3a2 
                 KOSSKALQRPVAS 
                 93 
                 DR4 
               
               
                   
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
             
               
               
               
             
           
               
                 TABLE 2 
               
             
             
               
                   
               
               
                 Antigenic determinants of p53 
               
             
          
           
               
                   
                 SEQ ID NO: 
               
               
                   
                   
               
             
          
           
               
                   
                 antigenic determinants of p53 binding to HLA-A1: 
                   
               
               
                   
                 RVEGNLARVEY (196-205) 
                 94 
               
               
                   
                 GSDCTTIHY (226-234) 
                 95 
               
               
                   
                 antigenic determinants of p53 binding to HLA-A2: 
               
               
                   
                 LLPENNVLSPL (25-35) 
                 96 
               
               
                   
                 RMPEAAPPV (65-73) 
                 97 
               
               
                   
                 RMPEAAPRV 
                 98 
               
               
                   
                 ALNKMFCQL (129-137) 
                 99 
               
               
                   
                 STPPPGTRV (149-157) 
                 100 
               
               
                   
                 GLAPPQHLIRV (187-197) 
                 101 
               
               
                   
                 LLGRNSFEV (264-272) 
                 102 
               
               
                   
                 PLDGEYFTL (322-330) 
                 103 
               
               
                   
                 antigenic determinants of p53 binding to HLA-A3: 
               
               
                   
                 RVRAMAIYK (156-164) 
                 104 
               
               
                   
                 RRTEEENLR (282-290) 
                 105 
               
               
                   
                 ELPPGSTKR (298-306) 
                 106 
               
               
                   
                 antigenic determinants of p53 binding to HLA-B7: 
               
               
                   
                 LPENNVLSPL (26-35) 
                 107 
               
               
                   
                 APRMPEAAPPV (63-73) 
                 108 
               
               
                   
                 APRMPEAAPRV 
                 109 
               
               
                   
                 APPQHLIRV (189-197) 
                 110 
               
               
                   
                 RPILTIITL (249-257) 
                 111 
               
               
                   
                 KPLDGETYFTL (321-330) 
                 112 
               
               
                   
                 antigenic determinants of p53 binding to HLA-B8: 
               
               
                   
                 CQLAKTCPV (135-143) 
                 113 
               
               
                   
                 GLAPPQHLI (187-195) 
                 114 
               
               
                   
                 NTFRHSVVV (210-218) 
                 115 
               
               
                   
                 antigenic determinants of p53 binding to HLA-B51: 
               
               
                   
                 LLPENNVLSPL (25-35) 
                 116 
               
               
                   
                 RMPEAAPPV (65-73) 
                 117 
               
               
                   
                 LIRVEGNLRV (194-203) 
                 118 
               
               
                   
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
             
           
               
                 TABLE 3 
               
               
                   
               
               
                 Antigenic determinants of proteins E 6  and E 7   
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 YMLDLQPETT (E7 11-20) 
                 SEQ ID NO: 119 
               
               
                 LLMGTLGIV (E7 82-90) 
                 SEQ ID NO: 120 
               
               
                 TLGIVCPI (E7 86-93) 
                 SEQ ID NO: 121 
               
               
                 TIHDIILECV (E6 29-38) 
                 SEQ ID NO: 122 
               
               
                 KLPQLCTEL (E6 18-26) 
                 SEQ ID NO: 123 
               
               
                 RPPKLPQL (E6 8-15) 
                 SEQ ID NO: 124 
               
               
                 LRREVYDFAFRDLCIVYRDGNPY (E6 45-67) 
                 SEQ ID NO: 125 
               
               
                 ISEYRHYCY (E6 80-88) 
                 SEQ ID NO: 126 
               
               
                 EKQRHLDKKQRFHNIRGRWT (E6 121-140) 
                 SEQ ID NO: 127 
               
               
                 GQAEPDRAHYNIVTF (E7 43-57) 
                 SEQ ID NO: 284 
               
               
                 QAEPDRAHY (E7 44-52) 
                 SEQ ID NO: 128 
               
               
                 EPDRAHYNIV (E7 46-55) 
                 SEQ ID NO: 129 
               
               
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
             
           
               
                 TABLE 4 
               
               
                   
               
               
                 Antigenic determinants of the HIV-1 virus 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 HLA-A1 
                   
               
               
                 (Nef 96-106: GLEGLIHSQRR 
                 SEQ ID NO: 130 
               
               
                 (Nef 121-128: FPDWQNYT 
                 SEQ ID NO: 131 
               
               
                 (Nef 137-145: LTFGWCYKL 
                 SEQ ID NO: 132 
               
               
                 (Nef 184-191: RFDSRLAF 
                 SEQ ID NO: 133 
               
               
                 (Nef 195-202: ARELHPEY 
                 SEQ ID NO: 134 
               
               
                 HLA-A2 
               
               
                 Gp120 121-129: KLTPLCVTL 
                 SEQ ID NO: 135 
               
               
                 P17 77-85: SLYNTVATL 
                 SEQ ID NO: 136 
               
               
                 RT 200-208: ALVEICTEM 
                 SEQ ID NO: 137 
               
               
                 RT 275-285: VLDVGDAYFSV 
                 SEQ ID NO: 138 
               
               
                 RT 346-354: KIYQYMDDL 
                 SEQ ID NO: 139 
               
               
                 RT 368-376: KIEELRQHL 
                 SEQ ID NO: 140 
               
               
                 RT 376-387: LLRWGLTTPDK 
                 SEQ ID NO: 141 
               
               
                 RT 476-484: ILKEPVHGV 
                 SEQ ID NO: 142 
               
               
                 RT 588-596: PLVKLWYQL 
                 SEQ ID NO: 143 
               
               
                 RT 683-692: ELVNQIIEQL 
                 SEQ ID NO: 144 
               
               
                 Nef 136-145: PLTFGWCFKL 
                 SEQ ID NO: 145 
               
               
                 Nef 180-189: VLQWRFDSRL 
                 SEQ ID NO: 146 
               
               
                 Nef 190-198: ALHHVAREL 
                 SEQ ID NO: 147 
               
               
                 Gp41 818-826: SLLNATVDI 
                 SEQ ID NO: 148 
               
               
                 P24 183-191: DLNTMLNTV 
                 SEQ ID NO: 149 
               
               
                 RT 346-354: VIYQYMDDL 
                 SEQ ID NO: 150 
               
               
                 RT 588-596: PLVKLWYQL 
                 SEQ ID NO: 152 
               
               
                 Pro 143-152: VLVGPTPVNI 
                 SEQ ID NO: 151 
               
               
                 (Gp120 37-44: TVYYGVPV 
                 SEQ ID NO: 153 
               
               
                 (Gp120 115-122: SLKPCVKL 
                 SEQ ID NO: 154 
               
               
                 (Gp120 313-321: RIQRGPGRA 
                 SEQ ID NO: 155 
               
               
                 (Gp120 197-205: TLTSCNTSV 
                 SEQ ID NO: 156 
               
               
                 (Gp120 428-435: FINMWQEV 
                 SEQ ID NO: 157 
               
               
                 (Gp 41 836-844: VVQGAYRAI 
                 SEQ ID NO: 158 
               
               
                 (p24 219-228: HAGPIAPGQM 
                 SEQ ID NO: 159 
               
               
                 (p15 422-431: QMKDCTERQA 
                 SEQ ID NO: 160 
               
               
                 (p15 448-456: FLQSRPETA 
                 SEQ ID NO: 161 
               
               
                 (RT 681-691: ESELVNQIIEG 
                 SEQ ID NO: 162 
               
               
                 HLA-A3 
               
               
                 P17 18-26: KIRLRPGGK 
                 SEQ ID NO: 163 
               
               
                 P17 20-28: RLRPGGKKK 
                 SEQ ID NO: 164 
               
               
                 RT 200-210: ALVEICTEMEK 
                 SEQ ID NO: 165 
               
               
                 RT 325-333: AIFQSSMTK 
                 SEQ ID NO: 166 
               
               
                 RT 359-368: DLEIGQHRTK 
                 SEQ ID NO: 167 
               
               
                 Nef 73-82: QVPLRPMTYK 
                 SEQ ID NO: 168, 174, 
               
               
                   
                 12, 215 
               
               
                 Gp120 37-46: TVYYGVPVWK 
                 SEQ ID NO: 169 
               
               
                 Gp41 775-785: RLRDLLLIVTR 
                 SEQ ID NO: 170 
               
               
                 P17 18-26: KIRLRPGGK 
                 SEQ ID NO: 171 
               
               
                 HLA-A11 
               
               
                 RT 325-333: AIFQSSMTK 
                 SEQ ID NO: 172 
               
               
                 RT 507-517: QIYQEPFKNLK 
                 SEQ TD NO: 173 
               
               
                 Nef 73-82: QVPLRPMTYK 
                 SEQ ID NO: 174, 12, 
               
               
                   
                 215, 168 
               
               
                 Nef 84-92: AVDLSHFLK 
                 SEQ ID NO: 175, 15 
               
               
                 p24 349-359: ACQVGGPGHK 
                 SEQ ID NO: 176 
               
               
                 P17 83-91: ATLYCVHQR 
                 SEQ ID NO: 177 
               
               
                 HLA-A24 (A9) 
               
               
                 Gp120 52-61: LFCASDAKAY 
                 SEQ ID NO: 178 
               
               
                 Gp41 591-598: YLKDQQLL 
                 SEQ ID NO: 180 
               
               
                 or 590-597 RYLKDQQL 
                 SEQ ID NO: 179 
               
               
                 (RT 484-492: VYYDPSKDL 
                 SEQ ID NO: 181 
               
               
                 (RT 508-516: IYQEPFKNL 
                 SEQ ID NO: 182 
               
               
                 (RT 681-691: ESELVNQIIEG 
                 SEQ ID NO: 183 
               
               
                 HLA-A25 (A10) 
               
               
                 P24 203-212: ETINEEAAEW 
                 SEQ ID NO: 184 
               
               
                 HLA-A26 (A10) 
               
               
                 P24 167-175: EVIPMFSAL 
                 SEQ ID NO: 185 
               
               
                 HLA-A30 (A19) 
               
               
                 (Gp41 845-852: RAIRHIPRR 
                 SEQ ID NO: 186 
               
               
                 HLA-A31 (A19) 
               
               
                 (Gp41 775-785: RLRDLLLIVTR 
                 SEQ ID NO: 187 
               
               
                 HLA-A32 (A19) 
               
               
                 Gp120 424-432: RIKQIINMW 
                 SEQ ID NO: 188 
               
               
                 (Gp41 774-785: HRLRDLLLI 
                 SEQ ID NO: 189 
               
               
                 RT 559-568: PIQKETWETW 
                 SEQ ID NO: 190 
               
               
                 HLA-A33 (A19) 
               
               
                 (P24 266-275 :IILGLNKIVR 
                 SEQ ID NO: 191 
               
               
                 HLA-B7 
               
               
                 RT 699-707: YLAWVPAHK 
                 SEQ ID NO: 192, 197 
               
               
                 Nef 68-77: FPVTQVPLR 
                 SEQ ID NO: 194 
               
               
                 Nef 128-137: TPGPGVRYPL 
                 SEQ ID NO: 193 
               
               
                 Gp120 303-312:RPNNNTRKSI 
                 SEQ ID NO: 195 
               
               
                 Gp41 848-856: IPRRIRQGL 
                 SEQ ID NO: 196 
               
               
                 RT 699-707: YLAWVPAHK 
                 SEQ ID NO: 197, 192 
               
               
                 HLA-B8 
               
               
                 Gp120 2-10: RVKEKYQHL 
                 SEQ ID NO: 198 
               
               
                 P17 24-32 :GGKKKYKLK 
                 SEQ ID NO: 199 
               
               
                 Nef 90-97: FLKEKGGL 
                 SEQ ID NO: 200, 22 
               
               
                 P24 259-267: GEIYKRWII 
                 SEQ ID NO: 201 
               
               
                 Gp41 591-598: YLKDQQLL 
                 SEQ ID NO: 202 
               
               
                 (Gp41 849-856: PRRIRQGL 
                 SEQ ID NO: 203 
               
               
                 or 851-859: RIRQGLERIL 
                 SEQ ID NO: 204 
               
               
                 (P24 329-337: DCKTILKAL 
                 SEQ ID NO: 205 
               
               
                 (RT 185-193: GPKVKQWPL 
                 SEQ ID NO: 206 
               
               
                 (Nef 182-189: EWRFDSRL 
                 SEQ ID NO: 207 
               
               
                 HLA-B14 
               
               
                 Gp41 589-597: ERYLKDQQL 
                 SEQ ID NO: 208 
               
               
                 P24 298-306: DRFYKTLRA 
                 SEQ ID NO: 210 
               
               
                 (P24 183-191?: DLNTMLNTV 
                 SEQ ID NO: 209 
               
               
                 (p24 304-313: LRAEQASVQEV 
                 SEQ ID NO: 211 
               
               
                 (p24 305-313: RAEQASVQEV 
                 SEQ ID NO: 212 
               
               
                 HLA-B18 
               
               
                 (Nef 135-143: YPLTFGWCY 
                 SEQ ID NO: 213 
               
               
                 (Nef 135-143: YPLTFGWCF 
                 SEQ ID NO: 214 
               
               
                 HLA-B27 
               
               
                 P24 263-272: KRWIILGLNK 
                 SEQ ID NO: 10 
               
               
                 Nef 73-82: QVPLRPMTYK 
                 SEQ ID NO: 215, 12, 
               
               
                   
                 174, 168 
               
               
                 Nef 134-141: RYPLTFGW 
                 SEQ ID NO: 19 
               
               
                 or 133-141: YPLTFGW 
                 SEQ ID NO: 216 
               
               
                 Gp41 589-597 ERYLKDQQL 
                 SEQ ID NO: 217 
               
               
                 (Gp41 791-800: GRRGWEALKY 
                 SEQ ID NO: 218 
               
               
                 HLA-B35 
               
               
                 Gp120 78-86: DPNPQEVVL 
                 SEQ ID NO: 219 
               
               
                 Gp120 257-265: RPVVSTQLL 
                 SEQ ID NO: 220 
               
               
                 RT 285-294: VPLDKDFRKY 
                 SEQ ID NO: 221 
               
               
                 RT 323-331: SPAIFQSSM 
                 SEQ ID NO: 222 
               
               
                 RT 342-350: NPDIVTYQY (consensus clade B) 
                 SEQ ID NO: 223 
               
               
                 RT 460-468: IPLTEEAEL 
                 SEQ ID NO: 224 
               
               
                 RT 598-608: EPIVGAETFY 
                 SEQ ID NO: 225 
               
               
                 Nef 68-76: FPVRPQVPL 
                 SEQ ID NO: 226 
               
               
                 Nef 74-81: VPLRPMTY 
                 SEQ ID NO: 13 
               
               
                 Gp41 611-619: TAVPWNASW 
                 SEQ ID NO: 227 
               
               
                 Gp120 42-52: VPVWKEATTTL 
                 SEQ ID NO: 228 
               
               
                 P17 124-132: NSSQVSQNY (consensus clade B) 
                 SEQ ID NO: 229 
               
               
                 P24 254-262: PPIPVGEIY(consensus clade B) 
                 SEQ ID NO: 9 
               
               
                 HLA-B37 
               
               
                 Nef 120-128: YFPDWQNYT 
                 SEQ ID NO: 17 
               
               
                 HLA-B44 (B12) 
               
               
                 P24 178-186: SEGATPQDL 
                 SEQ ID NO: 230 
               
               
                 (p24 175-184: LESGATPQDL 
                 SEQ ID NO: 231 
               
               
                 HLA-B51 (B5) 
               
               
                 gp41 562-570: RAIEAQQHL 
                 SEQ ID NO: 232 
               
               
                 RT 200-208: ALVEICTEM 
                 SEQ ID NO: 233 
               
               
                 RT 209-217: EKEGKISKI 
                 SEQ ID NO: 234 
               
               
                 RT 295-302: TAFTIPSI 
                 SEQ ID NO: 235 
               
               
                 HLA-B52 (B5) 
               
               
                 Nef 190-198: AFHHVAREL 
                 SEQ ID NO: 21 
               
               
                 HLA-B55 (B22) 
               
               
                 Gp120 42-51: VPVWKEATTT 
                 SEQ ID NO: 236 
               
               
                 HLA-B57 and B58 (B17) 
               
               
                 P24 240-249: TSLTQEQIGW 
                 SEQ ID NO: 237 
               
               
                 Nef 116-125: HTQGYFPDWQ 
                 SEQ ID NO: 238 
               
               
                 or 116-124: HTQGYFPDW 
                 SEQ ID NO: 239 
               
               
                 Nef 120-128: YFPDWQNYT 
                 SEQ ID NO: 17 
               
               
                 (P24 147-155: ISPRTLNAW 
                 SEQ ID NO: 240 
               
               
                 (P24 164-172: FSPEVIPMF 
                 SEQ ID NO: 241 
               
               
                 HLA-Bw62 (B15) 
               
               
                 P17 20-29: RLRPGGKKKY 
                 SEQ ID NO: 242 
               
               
                 P24 268-277: LGLNKIVRMY 
                 SEQ ID NO: 11 
               
               
                 RT 427-438: LVGKLNWASQIY 
                 SEQ ID NO: 243 
               
               
                 Nef 84-91: AVDLSHFL 
                 SEQ ID NO: 14 
               
               
                 Nef 117-127: TQGYFPDWQNY 
                 SEQ ID NO: 16 
               
               
                 HLA-Cw4 
               
               
                 gp120 380-388: SFNCGGEFF 
                 SEQ ID NO: 244 
               
               
                 HLA-Cw8 
               
               
                 RT 663-672: VTDSQYALGI 
                 SEQ ID NO: 245 
               
               
                 P24 305-313: RAEQASQEV 
                 SEQ ID NO: 246 
               
               
                 Nef 82-91: KAALDLSHPL 
                 SEQ ID NO: 247 
               
               
                 HLA-Cw? 
               
               
                 P24 308-316: QATQEVKNW 
                 SEQ ID NO: 248 
               
               
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
               
               
               
             
           
               
                 TABLE 5 
               
             
             
               
                   
               
               
                 Antigenic determinants of human melanoma 
               
             
          
           
               
                   
                   
                   
                 Amino 
                 SEQ 
               
               
                 Gene/ 
                 MHC 
                   
                 acid 
                 ID 
               
               
                 protein 
                 restriction 
                 Peptide 
                 positions 
                 NO: 
               
               
                   
               
               
                   
                 HLA-A2 
                 MLLAVLYCL 
                  1-9 
                 249 
               
               
                   
                 HLA-A2 
                 YMNGTMSQV 
                 369-377 
                 250 
               
               
                   
                   
                 YMDGTMSQV 
                   
                 252 
               
               
                   
                 HLA-A24 
                 AFLPWHRLF 
                 206-214 
                 251 
               
               
                   
                 HLA-B44 
                 SEIWRDIDF 
                 192-200 
                 253 
               
               
                   
                 HLA-DR4 
                 QNILLSNAPLGPQFP 
                  56-70 
                 254 
               
               
                   
                   
                 SYLQDSDPDSFQD 
                 450-462 
                 255 
               
               
                 Pmel17 gp100   
                 HLA-A2 
                 KTWGQYWQV 
                 154-162 
                 256 
               
               
                   
                 HLA-A2 
                 AMLGTHTMEV 
                 177-186 
                 257 
               
               
                   
                 HLA-A2 
                 MLGTHTMEV 
                 178-186 
                 258 
               
               
                   
                 HLA-A2 
                 ITDQVPFSV 
                 209-217 
                 259 
               
               
                   
                 HLA-A2 
                 YLEPGPVTA 
                 280-288 
                 260 
               
               
                   
                 HLA-A2 
                 LLDGTATLRL 
                 457-466 
                 261 
               
               
                   
                 HLA-A2 
                 VLYRYGSFSV 
                 476-485 
                 262 
               
               
                   
                 HLA-A2 
                 SLADTNSLAV 
                 570-579 
                 263 
               
               
                   
                 HLA-A3 
                 ALLAVGATK 
                  17-25 
                 264 
               
               
                 Melan-A MART-1   
                 HLA-A2 
                 (E)AAGIGILTV 
                 26(7)-35  
                 266, 
               
               
                   
                   
                   
                   
                 265 
               
               
                   
                 HLA-A2 
                 ILTVILGVL 
                  32-40 
                 267 
               
               
                 GP 75TRP-1   
                 HLA-A31 
                 MSLQRQFLR 
                   
                 268 
               
               
                 TRP-2 
                 HLA-A31 
                 LLGPGRPYR 
                 197-205 
                 269 
               
               
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 6 
               
             
             
               
                   
               
               
                 Tumour Antigenic determinants resulting from de mutations 
               
             
          
           
               
                   
                   
                   
                   
                 Amino 
                 SEQ 
               
               
                 Gene/ 
                   
                 MHC 
                   
                 acid 
                 ID 
               
               
                 protein 
                 Tumour 
                 restriction 
                 Peptide 
                 positions 
                 NO: 
               
               
                   
               
               
                 MUM-1 
                 Melanoma 
                 HLA-B44 
                 EEKLIVVLF 
                 30-38 
                 270 
               
               
                 CDK4 
                 Melanoma 
                 HLA-A2 
                 ACDPHSGHFV 
                 23-32 
                 271 
               
               
                 β-catenine 
                 Melanoma 
                 HLA-A24 
                 SYLDSGIIF 
                 29-37 
                 272 
               
               
                 HLA-A2 
                 Renal car- 
                   
                   
                 — 
               
               
                   
                 cinoma 
               
               
                 CASP-8 
                 Squamous 
                 HLA-B35 
                 FPSDSWCYF 
                 476-484 
                 273 
               
               
                   
                 carcinoma 
               
               
                   
                 of head 
               
               
                   
                 and neck 
               
               
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 7 
               
             
             
               
                   
               
               
                 Antigens common to different tumours 
               
             
          
           
               
                   
                 Normal expression 
                 MHC 
                 Antigenic 
                 Amino acid 
                 SEQ ID 
               
               
                 Gene 
                 tissue 
                 restriction 
                 peptide 
                 positions 
                 NO: 
               
               
                   
               
               
                 MAGE-1 
                 Testicles 
                 HLA-A1 
                 EADPTGHSY 
                 161-169 
                 274 
               
               
                   
                   
                 HLA-Cw16 
                 SAYGEPRKL 
                 230-238 
                 275 
               
               
                 MAGE-3 
                 Testicles 
                 HLA-A1 
                 EVDPIGHLY 
                 168-176 
                 276 
               
               
                   
                   
                 HLA-A2 
                 FLWGPRALV 
                 271-279 
                 277 
               
               
                   
                   
                 HLA-B44 
                 MEVDPIGHLY 
                 167-176 
                 278 
               
               
                 BAGE 
                 Testicles 
                 HLA-Cw16 
                 AARAVFLAL 
                  2-10 
                 279 
               
               
                 GAGE-1/2 
                 Testicles 
                 HLA-Cw6 
                 YRPRPRRY 
                  9-16 
                 280 
               
               
                 RAGE-1 
                 Retina 
                 HLA-B7 
                 SPSSNRIRNT 
                 11-20 
                 281 
               
               
                 GnTV 
                 None 
                 HLA-A2 
                 VLPDVFLRC 
                 38-64 
                 282 
               
               
                 Mucin 
                 Breasts during 
                 no restriction 
                 PDTRPAPGSTAPPA 
                   
                 283 
               
               
                   
                 lactation 
                   
                 HGVTSA* 
               
               
                   
               
               
                 *Aberrant transcript of the N-acetyl glucosaminyl transferase V (GnTV) found only in melanomas 
               
             
          
         
       
     
     
       
         
               
               
               
             
           
               
                   
                 TABLE 8 
               
               
                   
                   
               
               
                   
                 LIPOPEPTIDES 
                 FILTRATION YIELD 
               
               
                   
                   
               
             
             
               
                   
                 NEF 66 
                 quantitative 
               
               
                   
                 NEF 117 
                 80% 
               
               
                   
                 NEF 182 
                 quantitative 
               
               
                   
                 GAG 183 
                 80% 
               
               
                   
                 GAG 253 
                 77% 
               
               
                   
                 ENV 
                 quantitative 
               
               
                   
                   
               
             
          
         
       
     
     
       
         
               
               
               
               
               
             
               
               
               
               
               
             
           
               
                 TABLE 9 
               
               
                   
               
               
                   
                   
                   
                 Volume 
                 Filtration 
               
               
                   
                   
                 Concentration 
                 removed 
                 yield (%) 
               
               
                 Peptide 
                 Solvent 
                 (mg/ml) 
                 (ml) 
                 after mixing 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 NEF 66 
                 water 
                 5 
                 1 
                 95 
               
               
                 NEF 117 
                 AcOH 25% 
                 5 
                 1 
                 81 
               
               
                 NEF 182 
                 AcOH 25% 
                 5 
                 1 
                 92 
               
               
                 GAG 183 
                 AcOH 80% 
                 10 
                 0.5 
                 73 
               
               
                 GAG 253 
                 AcOH 25% 
                 5 
                 1 
                 31 
               
               
                 ENV 
                 water 
                 5 
                 1 
                 95 
               
               
                   
               
             
          
         
       
     
     
       
         
               
               
               
               
               
             
           
               
                 TABLE 10 
               
               
                   
               
               
                   
                   
                   
                 Volume 
                 Filtration 
               
               
                   
                   
                 Concentration 
                 removed 
                 yield (%) 
               
               
                 Peptide 
                 Solvent 
                 (mg/ml) 
                 (ml) 
                 after mixing* 
               
               
                   
               
             
             
               
                 NEF 66 
                 AcOH 80% 
                 20 
                 0.250 
                 quantitative 
               
               
                 NEF 117 
                 AcOH 80% 
                 20 
                 0.250 
                 quantitative 
               
               
                 NEF 182 
                 AcOH 80% 
                 20 
                 0.250 
                 quantitative 
               
               
                 GAG 183 
                 AcOH 80% 
                 20 
                 0.250 
                 quantitative 
               
               
                 GAG 253 
                 AcOH 80% 
                 20 
                 0.250 
                 quantitative 
               
               
                 ENV 
                 AcOH 80% 
                 20 
                 0.250 
                 quantitative 
               
               
                   
               
               
                 *to within the precision of the determination 
               
             
          
         
       
     
     
       
         
               
               
               
               
               
               
             
           
               
                 TABLE 11 
               
               
                   
               
               
                   
                 Exact 
                 Pep- 
                 Quantity 
                 Quantity 
                   
               
               
                 Pep- 
                 weight*** 
                 tide 
                 expected* 
                 obtained*** 
               
               
                 tide 
                 (mg) 
                 net 
                 (μg per dose) 
                 (μg per dose) 
                 yield** (%) 
               
               
                   
               
             
             
               
                 NEF 
                 764 
                 641 
                 550 
                 505 ± 15 
                 89.14-94.6  
               
               
                 66 
               
               
                 NEF 
                 739 
                 641 
                 550 
                 621 ± 21 
                 109.08-116.72 
               
               
                 117 
               
               
                 NEF 
                 742 
                 641 
                 550 
                 545 ± 16 
                  96.23-102.05 
               
               
                 182 
               
               
                 GAG 
                 741 
                 642 
                 550 
                 478 ± 13 
                 84.50-89.23 
               
               
                 183 
               
               
                 GAG 
                 780 
                 641 
                 550 
                 571 ± 28 
                  98.76-108.95 
               
               
                 253 
               
               
                 ENV 
                 810 
                 642 
                 550 
                 593 ± 17 
                 104.71-110.89 
               
               
                   
               
               
                 *the target dose was 500 μg per peptide: an overdose of 10% was deliberately included at the time of weighing, given the yields obtained during the preparation of batch CK6 
               
               
                 **the yield ranges reflect the precision of the determination, and not a significant variation from one flask to another 
               
               
                 ***the values in excess are due to imprecisions in the weighings of electrostatic powders by an operator wearing a standard pressure suit 
               
             
          
         
       
     
     
       
         
               
             
               
               
               
               
               
               
               
             
           
               
                 TABLE 12 
               
               
                   
               
               
                 Test of uniformity of concentration 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                   
                 nef 66 
                 nef 117 
                 nef 182 
                 gag 183 
                 gag 253 
                 env 303 
               
               
                   
               
               
                   
                 14.40 
                 17.74 
                 16.19 
                 13.28 
                 16.74 
                 17.53 
               
               
                   
                 14.38 
                 17.75 
                 16.21 
                 13.27 
                 17.27 
                 17.63 
               
               
                   
                 14.67 
                 16.36 
                 16.61 
                 13.41 
                 16.89 
                 18.36 
               
               
                 sample 1 
                 14.49 
                 17.28 
                 16.34 
                 13.32 
                 16.97 
                 17.84 
               
               
                   
                 13.42 
                 17.11 
                 15.32 
                 12.66 
                 15.56 
                 16.36 
               
               
                   
                 13.81 
                 17.04 
                 15.32 
                 12.67 
                 15.89 
                 16.51 
               
               
                   
                 13.77 
                 17.06 
                 15.33 
                 12.45 
                 15.16 
                 16.41 
               
               
                 sample 2 
                 13.67 
                 17.07 
                 15.32 
                 12.59 
                 15.54 
                 16.43 
               
               
                   
                 13.58 
                 17.08 
                 15.33 
                 12.68 
                 15.64 
                 16.29 
               
               
                   
                 13.70 
                 17.08 
                 15.31 
                 12.62 
                 15.82 
                 16.28 
               
               
                   
                 13.59 
                 17.05 
                 15.31 
                 12.32 
                 14.85 
                 16.37 
               
               
                 sample 3 
                 13.62 
                 17.07 
                 15.32 
                 12.54 
                 15.44 
                 16.31 
               
               
                   
                 13.20 
                 16.80 
                 15.14 
                 12.23 
                 16.05 
                 16.15 
               
               
                   
                 14.53 
                 17.34 
                 15.74 
                 13.06 
                 15.93 
                 17.17 
               
               
                   
                 13.49 
                 16.86 
                 15.17 
                 12.31 
                 15.44 
                 16.15 
               
               
                 sample 4 
                 13.74 
                 17.00 
                 15.35 
                 12.53 
                 15.80 
                 16.49 
               
               
                   
                 13.88 
                 17.21 
                 15.40 
                 12.52 
                 14.78 
                 16.80 
               
               
                   
                 13.94 
                 17.17 
                 15.39 
                 12.59 
                 15.20 
                 16.72 
               
               
                   
                 13.98 
                 17.19 
                 15.47 
                 12.96 
                 15.49 
                 16.71 
               
               
                 sample 5 
                 13.94 
                 17.19 
                 15.42 
                 12.69 
                 15.16 
                 16.74 
               
               
                   
                 14.03 
                 17.26 
                 15.75 
                 11.62 
                 15.78 
                 16.97 
               
               
                   
                 13.99 
                 17.20 
                 15.73 
                 11.39 
                 15.77 
                 17.02 
               
               
                   
                 14.20 
                 17.26 
                 15.74 
                 12.19 
                 15.90 
                 16.80 
               
               
                 sample 6 
                 14.07 
                 17.24 
                 15.74 
                 11.73 
                 15.81 
                 16.93 
               
               
                   
                 13.78 
                 17.29 
                 15.67 
                 12.69 
                 16.13 
                 18.04 
               
               
                   
                 13.94 
                 17.22 
                 15.57 
                 12.67 
                 16.40 
                 17.50 
               
               
                   
                 13.95 
                 17.23 
                 15.55 
                 12.28 
                 16.19 
                 17.37 
               
               
                 sample 7 
                 13.89 
                 17.25 
                 15.60 
                 12.55 
                 16.24 
                 17.64 
               
               
                   
                 13.84 
                 17.06 
                 15.38 
                 12.50 
                 15.62 
                 17.90 
               
               
                   
                 13.65 
                 17.09 
                 15.45 
                 12.44 
                 16.02 
                 17.73 
               
               
                   
                 13.73 
                 16.94 
                 15.37 
                 nd 
                 16.21 
                 17.54 
               
               
                 sample 8 
                 13.74 
                 17.03 
                 15.40 
                 12.47 
                 15.95 
                 17.73 
               
               
                   
                 14.03 
                 17.40 
                 15.66 
                 12.77 
                 16.46 
                 18.56 
               
               
                   
                 14.07 
                 17.33 
                 15.72 
                 11.92 
                 16.61 
                 18.41 
               
               
                   
                 13.89 
                 17.39 
                 15.72 
                 12.68 
                 15.94 
                 18.37 
               
               
                 sample 9 
                 14.00 
                 17.37 
                 15.70 
                 12.46 
                 16.34 
                 18.45 
               
               
                   
                 13.34 
                 16.88 
                 15.33 
                 12.07 
                 14.70 
                 17.92 
               
               
                   
                 13.71 
                 17.24 
                 15.66 
                 12.36 
                 15.12 
                 18.50 
               
               
                   
                 13.53 
                 16.93 
                 15.44 
                 12.28 
                 14.44 
                 18.01 
               
               
                 sample 10 
                 13.53 
                 17.02 
                 15.48 
                 12.24 
                 14.76 
                 18.14 
               
               
                   
                 13.72 
                 17.22 
                 15.64 
                 12.41 
                 14.89 
                 18.32 
               
               
                   
                 13.75 
                 17.33 
                 15.72 
                 12.36 
                 14.82 
                 18.31 
               
               
                   
                 13.67 
                 17.21 
                 15.72 
                 11.86 
                 14.61 
                 18.69 
               
               
                 sample 11 
                 13.71 
                 17.25 
                 15.69 
                 12.21 
                 14.77 
                 18.44 
               
               
                   
                 13.62 
                 17.11 
                 15.60 
                 12.28 
                 14.75 
                 18.42 
               
               
                   
                 13.74 
                 17.13 
                 15.70 
                 12.44 
                 14.98 
                 18.31 
               
               
                   
                 13.75 
                 17.16 
                 15.63 
                 12.51 
                 15.37 
                 18.32 
               
               
                 sample 12 
                 13.70 
                 17.13 
                 15.65 
                 12.41 
                 15.03 
                 18.35 
               
               
                   
                 13.32 
                 16.36 
                 14.74 
                 12.47 
                 16.17 
                 15.44 
               
               
                   
                 13.31 
                 16.41 
                 14.68 
                 12.51 
                 16.26 
                 15.56 
               
               
                   
                 13.34 
                 16.38 
                 14.67 
                 12.53 
                 16.17 
                 15.43 
               
               
                 sample 13 
                 13.32 
                 16.38 
                 14.70 
                 12.50 
                 16.20 
                 15.48 
               
               
                   
                 13.76 
                 16.72 
                 14.75 
                 12.67 
                 16.10 
                 15.59 
               
               
                   
                 13.56 
                 16.35 
                 14.75 
                 12.64 
                 16.16 
                 15.64 
               
               
                   
                 13.60 
                 16.67 
                 14.76 
                 12.64 
                 16.06 
                 15.64 
               
               
                 sample 14 
                 13.64 
                 16.58 
                 14.76 
                 12.65 
                 16.10 
                 15.62 
               
               
                   
                 13.36 
                 16.40 
                 14.53 
                 12.48 
                 15.90 
                 15.64 
               
               
                   
                 13.41 
                 16.35 
                 14.57 
                 12.52 
                 15.84 
                 15.80 
               
               
                   
                 13.44 
                 16.43 
                 14.50 
                 12.46 
                 15.77 
                 15.60 
               
               
                 sample 15 
                 13.40 
                 16.39 
                 14.53 
                 12.49 
                 15.84 
                 15.68 
               
               
                 m 
                 13.69 
                 16.91 
                 15.28 
                 12.49 
                 15.81 
                 16.82 
               
               
                 standard 
                 0.27 
                 0.37 
                 0.42 
                 0.28 
                 0.59 
                 1.19 
               
               
                 deviation 
               
               
                 t&#39;s 
                 0.58 
                 0.79 
                 0.89 
                 0.59 
                 1.24 
                 2.51 
               
               
                 min 
                 13.11 
                 16.12 
                 14.39 
                 11.91 
                 14.57 
                 14.30 
               
               
                 max 
                 14.27 
                 17.70 
                 16.18 
                 13.08 
                 17.05 
                 19.33 
               
               
                 Min accepted 
                 11.64 
                 14.37 
                 12.99 
                 10.62 
                 13.44 
                 14.29 
               
               
                 (−15%) 
               
               
                 Max accepted 
                 15.74 
                 19.45 
                 17.58 
                 14.37 
                 18.18 
                 19.34 
               
               
                 (+15%) 
               
               
                 Observed 
                 4.23% 
                 4.67% 
                 5.84% 
                 4.70% 
                 7.84% 
                 14.95% 
               
               
                 deviation 
               
               
                   
               
               
                 t = 2.110 3 deviant values on sample 1 (probably dilution error) 
               
             
          
         
       
     
     
       
         
               
               
               
             
           
               
                 TABLE 13 
               
               
                   
               
               
                 anti-7 peptide 
                 Peptides 
                 Short peptides 
               
               
                 CTL lines 
                 recognized 
                 recognized 
               
               
                   
               
             
             
               
                 92102 
                 GAG 246-281 
                   
               
               
                 92105 
                 NEF 125-147 
               
               
                 92109 
                 NEF 101-126 
                 NEF 101-110 
               
               
                   
                   
                 NEF 116-126 
               
               
                   
                 NEF 125-147 
                 NEF 128-136 
               
               
                   
                 NEF 155-178 
                 NEF 169-178 
               
               
                   
                 NEF 201-225 
                 NEF 215-225 
               
               
                   
                 GAG 246-281 
               
               
                 92120 
                 GAG 246-281 
               
               
                 92125 
                 NEF 155-178 
                 NEF 169-178 
               
               
                 92129 
                 NEF 125-147 
                 NEF 128-136 
               
               
                   
                 NEF 155-178 
                 NEF 169-178 
               
               
                   
                 NEF 201-225 
                 NEF 201-211 
               
               
                   
                   
                 NEF 211-219 
               
               
                 92117 
                 negative 
               
               
                 92127 
                 NEF 101-126 
               
               
                   
                 NEF 125-147 
               
               
                   
                 NEF 155-178 
               
               
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
             
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 14 
               
             
             
               
                   
               
               
                 Detection of specific antibodies of peptides of proteins NEF, GAG and 
               
               
                 ENV of the HIV virus, in the serum of volunteers immunized with a 
               
               
                 mixture of six lipopeptides 
               
             
          
           
               
                   
                 Peptide recognized 
               
             
          
           
               
                 Volunteer a   
                 Recovery period 
                 N1 
                 N2 
                 N3 
                 G1 
                 G2 
                 E 
               
               
                   
               
             
          
           
               
                 V4.6 
                 W20 
                 2.1 
                 7.2 
                 1.0 
                 1.0 
                 10.2 
                 1.2 
               
               
                 V4.15 
                 W20 
                 1.3 
                 4.8 
                 1.2 
                 1.3 
                 11.2 
                 1.5 
               
               
                 V4.16 
                 W20 
                 1.2 
                 4.7 
                 1.2 
                 1.1 
                 9.7 
                 1.3 
               
               
                 V4.17 
                 W20 
                 1.7 
                 1.8 
                 1.0 
                 1.1 
                 8.0 
                 1.2 
               
               
                 V4.18 
                 W20 
                 1.1 
                 1.2 
                 1.0 
                 1.3 
                 2.2 
                 1.1 
               
               
                 V4.28 
                 W20 
                 7.8 
                 8.8 
                 1.5 
                 1 
                 15 
                 5.7 
               
               
                 V4.1 (QS21) 
                 W20 
                 3.1 
                 3.2 
                 1.1 
                 1.2 
                 11.5 
                 4.7 
               
               
                 V4.5 (QS21) 
                 W20 
                 1.2 
                 4.2 
                 1.3 
                 1.1 
                 8.1 
                 2.1 
               
               
                 V4.19 (QS21) 
                 W20 
                 1.2 
                 5.3 
                 1.2 
                 1.3 
                 5.1 
                 3.8 
               
               
                 V4.21 (QS21) 
                 W20 
                 1.2 
                 4.7 
                 1.0 
                 1.2 
                 9.3 
                 1.9 
               
               
                 V4.32 (QS21) 
                 W20 
                 6.6 
                 14 
                 1.8 
                 1.9 
                 21 
                 4 
               
               
                 V4.34 (QS21) 
                 W20 
                 7.1 
                 21.2 
                 1.2 
                 1.8 
                 36 
                 8 
               
               
                   
               
               
                   a The volunteers were immunized with six lipopeptides in the form of micelles, or with an adjuvant (QS21) 
               
               
                   b The serums of the volunteers were recovered before injection of the lipopeptides, and twenty weeks after. The three injections of the six lipopeptides were administered at 0.4 and 16 weeks. 
               
               
                   c The detection of the specific antibodies of the peptides of the HIV virus was performed using an ELISA assay with serum dilution to 1/100. The ELISA assay plates were covered with NEF 66-97 (N1), NEF 117-147 (N2), NEF 182-205 (N3), GAG 183-214 (G1), GAG 253-284 (G2) or V3 ENV 303-335 (E). 
               
             
          
         
       
     
     
       
         
               
             
               
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 15 
               
             
             
               
                   
               
               
                 Proliferative responses of the PBMC of the volunteers with lipopeptides NEF, GAG and ENV 
               
             
          
           
               
                   
                 Proliferation index c   
               
             
          
           
               
                   
                 Recovery 
                   
                   
                   
                   
                   
                   
                 Proliferation induced by 
               
               
                 Volunteer a   
                 period 
                 N1 
                 N2 
                 N3 
                 G1 
                 G2 
                 E 
                 the culture medium d   
               
               
                   
               
               
                 V4.6 
                 W0 
                 1.3 
                 1.0 
                 1.0 
                 1.3 
                 1.0 
                 1 
                 871 (±25) 
               
               
                   
                 W20 
                 2.4 
                 3.1 (±1) 
                 10 (±7)  
                 4.5 (±1.1) 
                 7.2 (±0.7) 
                 3.6 (±0.9) 
                 280 (±32) 
               
               
                 V4.15 
                 W0 
                 1.0 
                 1.0 
                 1.3 
                 1.0 
                 1.4 
                 1.5 
                 1657 (±182) 
               
               
                   
                 W20 
                 1.9 
                 2.2 
                 1.6 
                 1.2 
                 1.6 
                 2.1 
                 252 (±30) 
               
               
                 V4.16 
                 W0 
                 1.0 
                 1.2 
                 1.3 
                 1.3 
                 1.8 
                 1.5 
                 3830 (±232) 
               
               
                   
                 W20 
                 1.1 
                 1.1 
                 2.2 
                 4.6 (±0.6) 
                 3.6 (±0.5) 
                 3.9 (±0.7) 
                 1000 (±168) 
               
               
                 V4.17 
                 W0 
                 2.5 
                 1.3 
                 1.4 
                 1.9 
                 2.0 
                 2.3 
                 5708 (±470) 
               
               
                   
                 W20 
                 1.5 
                 1.1 
                 1.6 
                 2.0 
                 2.0 
                 2.8 
                 1228 (±54)  
               
               
                 V4.18 
                 W0 
                 1.0 
                 1.3 
                 1.5 
                 1.8 
                 3.3 (±0.7) 
                 1.3 
                 460 (±49) 
               
               
                   
                 W20 
                 nd 
                 nd 
                 nd 
                 nd 
                 nd 
                 nd 
                 nd 
               
               
                 V4.28 
                 W0 
                 1.3 
                 2.2 
                 1.7 
                 1.2 
                 1.2 
                 1.2 
                 869 (±36) 
               
               
                   
                 W20 
                 3.8 (±0.6) 
                 1.2 
                 21 (±2)  
                 1.2 
                 8.2 (±1.6) 
                 7.6 (±2.2) 
                 2558 (±186) 
               
               
                 V4.1 (QS21) 
                 W0 
                 1.0 
                 1.1 
                 1.0 
                 1.1 
                 1.0 
                 1.0 
                 3107 (±521) 
               
               
                   
                 W20 
                 nd 
                 nd 
                 nd 
                 nd 
                 nd 
                 nd 
                 nd 
               
               
                 V4.5 (QS21) 
                 W0 
                 1.5 
                 1.6 
                 1.5 
                 1.6 
                 1.5 
                 1.3 
                 341 (±20) 
               
               
                   
                 W20 
                 4.6 (±1.2) 
                   3.1 (±0.3) 
                 1.5 
                 2.0 
                 3.9 (±0.3) 
                 5.0 (±2.2) 
                 776 (±60) 
               
               
                 V4.19 (QS21) 
                 W0 
                 1.0 
                 1.1 
                 1.2 
                 1.1 
                 1.0 
                 1.0 
                  918 (±102) 
               
               
                   
                 W20 
                 24.3 (±3.1)  
                 8.5 (±5) 
                 4.4 (±1.2) 
                 3.1 (±2.5) 
                 11.0 (±2.7)  
                 9.4 (±2.8) 
                  497 (±168) 
               
               
                 V4.21 (QS21) 
                 W0 
                 1.3 
                 1.3 
                 1.2 
                 3.9 (±1)   
                 1.3 
                 1.4 
                 322 (±21) 
               
               
                   
                 W20 
                 6.5 (±3)   
                 1.4 
                 2.3 
                 2.8 
                 11.3 (±4)   
                 3.3 (±1.9) 
                 1052 (±82)  
               
               
                 V4.32 (QS21) 
                 W0 
                 1.0 
                 1.0 
                 1.1 
                 1.3 
                 1.2 
                 1.2 
                 4448 (±75)  
               
               
                   
                 W20 
                 1.0 
                 1.0 
                 1.7 
                 1.2 
                 10.1 (±1.5)  
                 0.9 
                 245 (±30) 
               
               
                 V4.34 (QS21) 
                 W0 
                 1.0 
                 1.1 
                 1.1 
                 1.2 
                 1.2 
                 1.2 
                 5383 (±309) 
               
               
                   
                 W20 
                 3.4 (±0.2) 
                 1.1 
                 3.3 (±0.1) 
                 2.2 
                 4.4 (±0.6) 
                 3.1 (±0.1) 
                 7381 (±280) 
               
               
                   
               
               
                   a The volunteers were immunized with six lipopeptides in the form of micelles, or with an adjuvant (QS21). 
               
               
                   b The PBMC of the volunteers were recovered before injection of the lipopeptides (W0), and during the twentieth week (W20). 
               
               
                   c 2 10 5  cells were cultivated with 1 μg/ml of the HIV lipopeptides and the proliferation was measured by incorporation of tritiated thymidine at day 6. The lipopeptides were N1, N2, N3, G1, G2, and E. The proliferation index obtained with the culture medium only was equal to 1. 
               
               
                   d The proliferative response (cpm) of the PBMC of the volunteers cultivated in the medium alone is given. All the PBMC samples proliferated in response to 1 μg/ml of PHA, PPD and SEB. 
               
             
          
         
       
     
     
       
         
               
             
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 16 
               
               
                   
               
               
                 Specificity of the CTL in the immunized volunteers 
               
               
                 % of specific lysis of the cells 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 Lipopeptide incubated with 
                 V4.6 a   
                 V4.16 
                 V4.18 
                 V4.28 
               
             
          
           
               
                 target cells 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
               
               
                   
               
               
                 E/T Ratio 
                  70/1 
                  70/1 
                 50/1 
                 50/1 
                 80/1 
                 80/1 
                 10/1 
                 10/1 
               
               
                 None 
                  5% 
                 11% 
                  2% 
                 12% 
                  8% 
                 14% 
                 5% 
                  8% 
               
               
                 NEF 66-97 
                  9% 
                 17% 
                  8% 
                 18% 
                 11% 
                 40% 
                 12% 
                 19% 
               
               
                 NEF 117-147 
                  9% 
                 16% 
                  2% 
                 13% 
                  6% 
                  6% 
                 19% 
                 12% 
               
               
                 NEF 182-205 
                  4% 
                 15% 
                  2% 
                 24% 
                  6% 
                  6% 
                  2% 
                  4% 
               
               
                 E/T Ratio 
                  70/1 
                  70/1 
                 30/1 
                 30/1 
                 55/1 
                 55/1 
                 10/1 
                 10/1 
               
               
                 None 
                  4% 
                 18% 
                  5% 
                  5% 
                  8% 
                  6% 
                  2% 
                  2% 
               
               
                 GAG 183-214 
                  7% 
                 14% 
                  9% 
                 10% 
                 nd 
                 nd 
                  2% 
                  2% 
               
               
                 GAG 253-284 
                  9% 
                 49% 
                 11% 
                 20% 
                  6% 
                 26% 
                  2% 
                  2% 
               
               
                   
               
             
          
           
               
                 Lipopeptide incubated with 
                 V4.5 (QS21) 
                 V4.19 (QS21) 
                 V4.21 (QS21) 
                 V4.34 (QS21) 
               
             
          
           
               
                 target cells 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
               
               
                   
               
               
                 E/T Ratio 
                 100/1 
                 100/1 
                 60/1 
                 60/1 
                 40/1 
                 40/1 
                 35/1 
                 35/1 
               
               
                 None 
                 16% 
                 31% 
                  2% 
                  6% 
                  2% 
                  2% 
                 10% 
                  2% 
               
               
                 NEF 66-97 
                 10% 
                 23% 
                  0% 
                 15% 
                  2% 
                  2% 
                  2% 
                  2% 
               
               
                 NEF 117-147 
                 18% 
                 47% 
                  2% 
                 27% 
                  2% 
                  2% 
                  2% 
                  2% 
               
               
                 NEF 182-205 
                 10% 
                 31% 
                  0% 
                  0% 
                  2% 
                  2% 
                  2% 
                  2% 
               
               
                 E/T Ratio 
                 140/1 
                 140/1 
                 60/1 
                 60/1 
                 46/1 
                 46/1 
                 35/1 
                 35/1 
               
               
                 None 
                 23% 
                 11% 
                  0% 
                  0% 
                  2% 
                  2% 
                  2% 
                  2% 
               
               
                 GAG 183-214 
                 21% 
                 11% 
                  0% 
                  0% 
                  2% 
                  2% 
                  2% 
                 23% 
               
               
                 GAG 253-284 
                 20% 
                 68% 
                  0% 
                  9% 
                  2% 
                  2% 
                  5% 
                  5% 
               
               
                   
               
             
          
           
               
                 Lipopeptide incubated with 
                 V4.6 a   
                 V4.16 
                 V4.18 
                 V4.28 
               
             
          
           
               
                 target cells 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
               
               
                   
               
               
                 E/T Ratio 
                  70/1 
                  70/1 
                 25/1 
                 25/1 
                   
                   
                 10/1 
                 10/1 
               
               
                 None 
                  3% 
                  6% 
                 32% 
                 23% 
                 nd 
                 nd 
                  2% 
                  2% 
               
               
                 V3 ENV 303-335 
                  2% 
                 36% 
                 12% 
                 49% 
                 nd 
                 nd 
                  2% 
                 17% 
               
               
                 E/T Ratio 
                   
                   
                 50/1 
                 50/1 
                   
                   
                 10/1 
                 10/1 
               
               
                 None 
                   
                   
                 13% 
                 23% 
                   
                   
                  2% 
                  2% 
               
               
                 anti-A1 
                   
                   
                  2% 
                 48% 
                   
                   
                  5% 
                 34% 
               
               
                 anti-A3 
                   
                   
                 nd 
                 nd 
                   
                   
                 nd 
                 nd 
               
               
                   
               
             
          
           
               
                 Lipopeptide incubated with 
                 V4.5 (QS21) 
                 V4.19 (QS21) 
                 V4.21 (QS21) 
                 V4.34 (QS21) 
               
             
          
           
               
                 target cells 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
                 W0 
                 W20 
               
               
                   
               
               
                 E/T Ratio 
                  60/1 
                 60/1 
                 60/1 
                 60/1 
                 86/1 
                 86/1 
                 35/1 
                 35/1 
               
               
                 None 
                 22% 
                 14% 
                  0% 
                  2% 
                  7% 
                 13% 
                  5% 
                  3% 
               
               
                 V3 ENV 303-335 
                 24% 
                 16% 
                  2% 
                  6% 
                  2% 
                 23% 
                  3% 
                  3% 
               
               
                 E/T Ratio 
                   
                   
                   
                   
                   
                   
                 35/1 
                 35/1 
               
               
                 None 
                   
                   
                   
                   
                   
                   
                  2% 
                  2% 
               
               
                 anti-A1 
                   
                   
                   
                   
                   
                   
                 nd 
                 nd 
               
               
                 anti-A3 
                   
                   
                   
                   
                   
                   
                  2% 
                  2% 
               
               
                   
               
               
                   a The volunteers were immunized with six lipopeptides in the form of micelles, or with an adjuvant (QS21). 
               
               
                   b The target cells were autologous PBMC sensitized with 10 μM of each of the lipopeptides, irradiated and marked with  51 Cr. 
               
               
                   c The chromium release assay was performed after three in vitro stimulations. The cytotoxic activity against autologous EBV cells incubated with the peptides or without peptides was measured in a release assay of 4 hours. The cytotoxic activity was considered as positive when the chromium release was 10% greater than that observed with the target cells alone. A1 and A3 correspond to EBV cells incubated with a group of peptides A1 (n 137-145, n 195-202, n 184-191, n 121-128 for V4.16 or n 183-191, n 121-128 for V4.28) and peptide A3 (n 73-82). 
               
               
                   d The E/T ratio (ratio effector cells/target cells) corresponds to 5 × 10 3  marked target cells, incubated with varying quantities of effector cells. 
               
             
          
         
       
     
     
       
         
               
             
               
               
             
               
               
               
               
               
             
               
               
               
             
               
               
               
               
               
             
           
               
                 TABLE 17 
               
               
                   
               
               
                 CD8 +  T cells secreting γ-interferon/ex vivo assay 
               
               
                 Number of cells secreting γ-interferon/1 × 10 6  cells 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                   
                 V4.18 A2/11 B44/60 
               
             
          
           
               
                 SEQ ID NO: 
                   
                   
                 W0 
                 W20 
               
               
                   
               
               
                 131 
                 HLA-A1 
                 NEF 121-128 
                   
                   
               
               
                 132 
                   
                 NEF 137-145 
                   
                   
               
               
                 133 
                   
                 NEF 184-191 
                   
                   
               
               
                 134 
                   
                 NEF 195-202 
                   
                   
               
               
                 145 
                 HLA-A2 
                 NEF 136-145 
                 0 
                 0 
               
               
                 147 
                   
                 NEF 190-198 
                 nd 
                 nd 
               
               
                 149 
                   
                 GAG 183-191 
                 nd 
                 nd 
               
               
                 174 
                 HLA-A11 
                 NEF 73-82 c   
                 0 
                 15 
               
               
                 175 
                   
                 NEF 84-92 
                 0 
                 55 
               
               
                   
                   
                 EBN 416-424 
                 500 
                 500 
               
               
                 200 
                 HLA-B8 
                 NEF 90-97 
               
               
                 207 
                   
                 NEF 182-189 
               
               
                  19 
                 HLA-B27 
                 NEF 134-141 
               
               
                  10 
                   
                 GAG 263-272 
               
               
                 214 
                 HLA-B18 
                 NEF 135-143 
               
               
                   
               
             
          
           
               
                   
                 V4.5 (QS21) A2/11 B18/27 
                 V4.21 (QS21) A1 B8 
               
             
          
           
               
                 SEQ ID NO: 
                 W0 
                 W20 
                 W0 
                 W20 
               
               
                   
               
               
                 131 
                   
                   
                 1 
                 41 
               
               
                 132 
                   
                   
                 1 
                 6 
               
               
                 133 
                   
                   
                 6 
                 26 
               
               
                 134 
                   
                   
                 1 
                 1 
               
               
                 145 
                 0 
                 4 
               
               
                 147 
                 4 
                 16 
               
               
                 149 
                 2 
                 16 
               
               
                 174 
                 0 
                 0 
               
               
                 175 
                 nd 
                 nd 
               
               
                   
                 66 
                 63 
               
               
                 200 
                   
                   
                 1 
                 51 
               
               
                 207 
                   
                   
                 1 
                 26 
               
               
                  19 
                 2 
                 14 
               
               
                  10 
                 0 
                 9 
               
               
                 214 
                 0 
                 9